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Growth factors have enormous clinical potential as they orchestrate all repair and regenerative 
processes in the body. However, their half-lives in vivo when applied alone are very short, on the 
order of minutes to hours. Therefore, large doses and multiple applications are necessary which 
is expensive and raises safety concerns considering their potency. To address this issue we 
developed a coacervate delivery system which protects growth factors from degradation and 
sustains and localizes their release at the site of injection. By imitating the native signaling 
environment involving ligands, proteoglycans, and cell receptors our delivery vehicle also 
enhances growth factor bioactivity, enabling the use of minute and clinically-safe dosages. This 
dissertation describes the translational potential of this growth factor therapy to address three 
significant clinical needs: 1) Diabetic wound healing, 2) Cardiac repair following myocardial 
infarction, 3) Bone regeneration for congenital defects and trauma. 
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1.0  INTRODUCTION 
1.1 REGENERATIVE THERAPIES: INSIGHTS AND CHALLENGES 
Regenerative therapies all consist of three components: cells, scaffolds, and signals (Fig. 1). 
Cells can be derived from many different sources and some examples include mesenchymal stem 
cells (MSCs), embryonic stem cells (ESCs), iPSC (induced pluripotent stem cells), and mature 
cells such as fibroblasts, myocytes, or osteoblasts, to name a few. We are able to synthesize 
scaffolds using a plethora of materials, both natural and synthetic. Finally, signals are 
incoporated in the form of growth factors, nucleic acids, or small molecules, among many others. 
These are the building blocks we have at our disposal, and in some cases we will combine all 
three of these components for application; in some cases, however, we can rely on the body to 
contribute one or more of these, depending on its capability. One thing often overlooked though 
is the importance of the extracellular matrix (ECM) which integrates these three components, 
and this will be a critical theme of this dissertation.  
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Figure 1.  Components of regenerative therapies.   
 
 
The research presented here focuses on growth factors as the signal components because 
they are the natural biomolecules that control all repair and regenerative processes in the human 
body. When injury occurs, growth factors are released from nearby cells and they bind to cell 
receptors on the same cell or different cells, activate an intracellular cascade, and eventually 
results in some functional output of the cell such as proliferation, migration, survival, or 
secretion of more signaling molecules. This occurs on a massive scale with the ultimate goal of 
repairing or regenerating that injured tissue. In theory, we should able to accelerate this process 
by strategic application of growth factors; furthermore, for some chronic conditions, we should 
also be able to stimulate healing that would otherwise never occur naturally.  
Growth factors have one key limitation for regenerative therapies; they are highly 
unstable in the body when applied alone, with half-lives on the order of minutes to hours. This is 
due to proteolytic degradation and rapid dilution and systemic uptake and removal from where 
they are applied. Therefore a delivery vehicle is imperative to: 1) Protect the growth factors from 
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degradation, 2) Localize them to the site where they are needed, and 3) Slowly release them over 
time thereby extending their bioactivity. 
1.2 CONTROLLED PROTEIN DELIVERY 
Numerous delivery systems have been developed for growth factors. Naturally-derived 
materials including collagen and fibrin were proposed for growth factor delivery more than 20 
years ago.[1] Since then other materials including polysaccharides such as CMC, chitosan, and 
alginate and synthetic polymers including poly(lactic-co-glycolic acid) (PLGA) blends and 
polyethylene glycol (PEG) have also been utilized.[2-4] However, it was quickly realized that 
simple sponges and gels do not provide adequate exposure time of growth factors to cells within 
the target tissue. To extend release, groups have employed various cross-linking techniques[5] or 
directly fused binding sites with affinity for the scaffold onto the growth factors of interest.[6, 7] 
Microparticles have also become a highly studied group of controlled release vehicles.[8] 
However, these delivery strategies all overlook the essential role of the extracellular matrix in 
protection and translocation of growth factors within the tissue. Heparin-based delivery systems 
advantageously imitate the native signaling environment involving ECM proteoglycans, ligands 
and cell receptors.[9-12] Heparin has been incorporated into particle [13, 14] and gel-based 
delivery systems previously,[15-17] however none have proven safe and efficacious to be used 
clinically.  Additionally, these classical delivery systems often require harsh organic solvents or 
toxic cross-linking agents to prepare which significantly reduce growth factor bioactivity.[18, 
19] Circumventing this drawback, we developed a coacervate which could be formed and 
injected in aqueous solution, fully protecting protein activity.[20] Furthermore, heparin-based 
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coacervate delivery enhances the bioactivity of released growth factors,[21] significantly 
reducing the dosage necessary to achieve therapeutic efficacy. This potentiation is owed to 
imitation of the natural signaling environment, as described above. 
1.3 DRUG DELIVERY SYSTEMS FOR WOUND HEALING 
Wound healing is a highly coordinated process which relies on precise spatiotemporal 
presentation of signals to succeed. Significant progress has been made in identifying these 
signaling molecules and their mechanisms of action in both healthy and diseased states [22-26]. 
Consequently, there has also been great interest in applying these signals therapeutically to 
accelerate healing, or enable healing which will otherwise never occur naturally. The current 
limitation for therapies involving proteins, genes, and small molecule drugs has been a delivery 
system which can effectively enable their full therapeutic benefit. Namely, a delivery system in 
the context of wound healing should do the following for its cargo: 1) Maintain its bioactivity 
through protection from proteolysis in the wound bed, 2) Localize its bioavailability by 
preventing rapid dilution in wound fluid and systemic uptake and distribution, 3) Facilitate its 
release or presentation within the wound at a physiologically relevant rate and duration. If these 
goals are achieved, a successful delivery system will also minimize the dosage and application 
frequency necessary for efficacy.  
Here we aim to highlight recent advances in delivery systems for wound healing 
applications. As the topic has been thoroughly reviewed several times in the past [27-29], we 
place particular emphasis on those systems developed in recent years. We identify 5 vehicle 
types which include hydrogels, scaffolds, particles, complexes, and coacervates (Fig. 2) and 
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provide numerous examples to discuss their advantages and potential drawbacks. In effort to 
provide adequate depth, we limit our scope to biomaterial-based delivery systems for proteins 
and small molecule drugs with demonstrated efficacy for skin wound healing but not bone, 
muscle, or other epithelial defects such as those of the cornea. We include several systems for 
sustained release of genes and plasmids but not trans-membrane vehicles for gene transfer as 
these have a separate set of criteria and limitations [30, 31]. We also exclude biomaterial 
scaffolds for delivering cells in the classical tissue engineering paradigm, as well as therapies 
which have already received FDA approval as these have been reviewed extensively [32-34]. 
 
 
 
Figure 2. Five types of delivery systems. 
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1.3.1 Hydrogels 
Hydrogels are one of the most highly utilized delivery vehicles. They are versatile, able to form 
from nearly any water-soluble polymer. They also feature a number of tunable parameters such 
as porosity, swelling ratio, and cross-link density to offer some control over release rate. A final 
advantage is that to an extent, they may mimic the mechanical properties of the granulation 
tissue and maintain a moist wound environment [27, 35].  
Hydrogels are often formed from naturally occurring materials because of their 
abundance and good biocompatibility. Chitosan is one such natural hydrogel commonly 
employed in controlled release vehicles, appealing in part for its inherent benefits in the wound 
healing process [36]. Chitosan membranes have been used to cover a wound and slowly release 
antibiotics such as silver sulfadiazine as they swell. These membranes can be single layer [37] or 
bilayer [38], and their release may be tuned by variable addition of a second component such as 
alginate [39]. Chitosan sponges have also been described for controlled release of several 
different antibiotics to prevent microorganism infection [40-43] and have been evaluated in vivo 
[44]. Chitosan hydrogels delivering fibroblast growth factor-2 (FGF-2) have proved successful in 
extending the protein’s bioactivity and improving wound repair in diabetic mice [45, 46]. 
Another major advantage of hydrogels for wound healing applications is that they may be 
designed to polymerize on demand and thereby conform to the defect space. For example, 
chitosan hydrogels, designed to polymerize by enzyme-catalyzed cross-linking as injected into 
the defect, and were used to delivery rutin, a flavonol glycoside with healing properties  [47]. 
Similarly, photo-cross-linkable chitosan hydrogels have been developed to polymerize in the 
wound after 20s of exposure to UV light [48]. 
 7 
Fibrin is another naturally derived material often used in wound healing applications, 
owed to its involvement in wound hemostasis [49]. In one intriguing study, fibrin was tethered to 
plasmid hypoxia-inducible factor-1α (HIF-1α) via a peptide linker which resulted in a robust 
angiogenic response within the wound bed [50]. In another case, fibrin was employed as a carrier 
for adenovirus-mediated endothelial nitric oxide synthase (eNOS) gene transfer which up-
regulated wound nitric oxide (NO) levels [51]. Interestingly, the release mechanism of 
adenovirus in this approach is through fibrinolysis, initiated by local cells which are then 
promptly transfected [52]. This therapy was then advanced to co-deliver plasmid eNOS with the 
Rab18 gene which regulates inflammatory cytokine and proteolytic enzyme secretion. This 
unique approach targeting angiogenesis, inflammation, and proteolysis was tested in a 
hyperglycemic ulcer model using rabbits and led to numerous positive healing measures [53]. 
Growth factors have also been delivered using fibrin gel. For example, delivered keratinocyte 
growth factor (KGF) successfully stimulated healing in a skin-grafted humanized mouse model 
[6]. Likewise, fibroblast growth factor-1 (FGF-1) delivered by a modified fibrin gel resulted in 
angiogenesis and may potentially be used to treat chronic wounds [54, 55]. 
 A common strategy to facilitate delivery vehicle loading is to conjugate heparin or other 
glycosaminoglycans with affinity to growth factors, cytokines and morphogens [56].  Heparin-
conjugated fibrin was developed to sequester heparin-binding factors from platelet-rich plasma 
(PRP) including vascular endothelial growth factor (VEGF), platelet-derived growth factor 
(PDGF), and FGF-2, and provide their sustained release. When applied to full-thickness mouse 
wounds, healing measures such as epithelialization and angiogenesis were enhanced compared 
with PRP alone or unmodified fibrin [57]. These results demonstrate the importance of protein 
loading and stabilization in development of delivery systems, particularly those for proteins with 
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short half-lives.  Drawing too from this concept, synthetic extracellular matrix (ECM) films were 
formed by cross-linking chondroitin sulfate and heparan sulfate and loaded with FGF-2. When 
applied to large excisional wounds on genetically diabetic db/db mice, the films induced 
dramatically faster wound closure by mimicking native ECM function in the wound bed [58].    
In another utilization of natural materials, gelatin-hyaluronate sponges were loaded with 
epidermal growth factor (EGF) and silver sulfadiazine. In rat excisional wounds, the two 
molecules acted synergistically to significantly reduce inflammation and increase cell 
proliferation in the early stages of healing [59]. A hydrogel of pure alginate was developed for 
the targeted, short term release of SDF-1α protein which improved healing of incisional wounds 
in pigs [60] and excisional wounds in mice [61]. Finally, combining these materials in a 
composite matrix of gelatin and oxidized alginate allowed the slow release of a cyclic adenosine 
monophosphate (cAMP) analog which influenced keratinocyte proliferation and migration, 
ultimately accelerating re-epithelialization of full-thickness wounds in rats [62, 63].  
Synthetic polymers, while lacking the inherent biocompatibility of natural materials, do 
feature highly controllable and reproducible material properties [64]. Polyethylene glycol (PEG) 
is one of the most widely utilized hydrophilic polymers for drug delivery and is known for its 
good biocompatibility [65]. A disulfide cross-linked PEG hydrogel was developed for the 
sustained release of doxycycline for wound healing. This vehicle was evaluated in an interesting 
mouse model of chemical warfare wounds. Skin permeation of doxycycline was enhanced by the 
hydrogel which correlated to better wound healing measures [66]. PEG was also combined with 
another common synthetic polymer, poly(ɛ-caprolactone) (PCL), in a hydrogel for sustained 
release of micelles containing curcumin, a natural drug derived from the turmeric plant which 
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has healing properties. Curcumin-delivering hydrogels successfully enhanced healing of both 
incisional and excisional wounds on rats [67]. 
Although hydrogels have been used successfully in numerous pre-clinical wound models, 
they do suffer one significant drawback as delivery vehicles. The nature of their formation and 
composition leads to a large burst release due to partial non-loading of the drug or its rapid efflux 
from the gel as it swells [68]. This can be particularly dangerous because systemic drug levels 
may become elevated and lead to unwanted side effects at distal locations. Regranex®, an FDA-
approved carboxymethylcellulose hydrogel containing PDGF and indicated for diabetic ulcers, 
serves as an unfortunate example.  A retrospective study found that it led to increased risk of 
cancer mortality and resulted in a black box warning issued by the FDA in 2008 [69]. 
1.3.2 Scaffolds 
Scaffold is a general term, so in this section we will specifically discuss porous scaffolds which 
are implanted rather than injected or polymerized in situ as is possible with hydrogels. This is 
usually not a drawback for wound healing applications as most wounds are superficial and 
relatively easy to access for manipulation. In fact, a scaffold may be the best choice when good 
mechanical properties or a long degradation time are desired. Their 3-D structure also 
encourages cell infiltration and enables strategic patterning of stimuli to precisely direct tissue 
regeneration [35]. 
Natural materials are often utilized in scaffolds similar as hydrogels, though they need 
not necessarily be hydrophilic. Collagen is most common and there are well-established methods 
for reducing its antigenicity and applying cross-links for long-term mechanical stability [70]. In 
one example, curcumin-incorporated collagen matrices (CICM) were developed to improve full-
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thickness wound healing in rats [71]. The same collagen scaffold was used to release Glycyl-
histidyl-lysine (GHK), a matrikine with numerous healing properties such as angiogenesis and 
growth factor activation [72, 73]. Interestingly, the group has also investigated the sustained 
release of both reactive oxygen species (ROS) [74], and antioxidants [75] into the wound bed. 
FGF-2 impregnated pure gelatin sheets were also demonstrated to improve the granulation region 
thickness and collagen density in diabetic rat wounds [76]. These sheets also demonstrated 
efficacy in several patients with chronic non-healing wounds, however a randomized controlled 
clinical trial is necessary to conclusively assess the benefit of this therapy. An advanced wound 
dressing was formed from chitosan cross-linked collagen loaded with FGF-1 and demonstrated 
accelerated healing of diabetic rat wounds [77]. FGF-2 was also delivered by a collagen-gelatin 
scaffold  and tested in normal wounds [78], and furthermore in a diabetic pressure ulcer model 
using mice [79]. In another study, the release of platelet lysate from the same scaffold was 
evaluated and a dose-dependent response of lysate concentration on wound healing outcomes 
was observed [80]. A “gene-activated” bilayer dermal equivalent (BDE) was constructed from a 
collagen-chitosan sponge and contained plasmid DNA encoding for VEGF complexed with a 
non-viral gene delivery vector. The BDE enhanced vessel density and overall tensile strength of 
newly formed dermal tissue in both full-thickness excisional wounds [81] and burn wounds [82] 
in pigs.  
Drug loading of scaffolds is often by adsorption or entrapment and is therefore poor for 
some non-ideal drug-scaffold combinations. One method of improving loading efficiency is by 
modifying the therapeutic protein itself. In one instance, VEGF was modified with a collagen-
binding domain which enhanced its affinity to the endogenous ECM and retention in the 
granulation tissue 7 days after application to rat wounds [83]. The fusion protein was then loaded 
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into a collagen scaffold with enhanced  efficiency and greatly improved vascularization in 
diabetic rats, also reducing VEGF levels in the serum compared to the native protein [84]. A 
similar approach was used to modify neuronal growth factor (NGF) and demonstrated 
accelerated re-epithelialization in a rabbit ischemic ulcer model [85].  
Another natural material, hyaluronic acid (HA), was used to form sponges for the 
sustained release of EGF and arginine, which accelerated epithelialization of diabetic rat wounds 
by inducing moderate inflammation in the early stage of healing [86]. Similar sponges also 
containing collagen were found to induce better neovascularization in a genetically type 2 
diabetic mouse model compared to a commercial artificial skin [87]. 
Scaffolds developed using synthetic polymers often employ the fabrication technique of 
electrospinning. Electrospun scaffolds offer advantages of high surface area and tunable fiber 
diameter which may closely match those of native ECM proteins, promoting cell adhesion [88]. 
Core-sheath type electrospun poly(ethylene glycol)-poly(D,L-lactide) (PELA) nanofiber mats 
containing FGF-2 were implanted into diabetic rat wounds where they enhanced angiogenesis 
after 2 weeks and the scaffolds degraded completely within 4 weeks [89]. The large surface area 
and porosity of electrospun scaffolds allows for rapid hydrolytic degradation of polymer fibers. 
Similar scaffolds were also developed to provide controlled release of plasmid FGF-2. When 
implanted into skin defects of diabetic rats they led to improvements in numerous healing 
measures [90]. PEG/PCL block copolymer nanofibers have also been synthesized with 
chemically-immobilized EGF on their surface [91]. These scaffolds had some moderate effects 
on the healing of normal mouse wounds, but the results were greatly enhanced by the addition of 
FGF-2 within the core of co-axial fibers [92]. Likewise, curcumin has also been delivered using 
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electrospun nanofiber mats of PEG/PCL  or PCL alone, which were shown to accelerate wound 
healing of normal rats and diabetic mice, respectively [93, 94]. 
Natural polymers are often difficult to electrospin on their own and are therefore blended 
with synthetic polymers. One group investigated chitosan and poly(ethylene oxide) (PEO) co-
electrospun with PRP as a growth factor source. The bioactivity of the proteins was 
demonstrated to withstand the electrospinning process with in vitro assays, however this therapy 
still requires in vivo validation [95]. In at least one report, chitosan scaffolds providing sustained 
release of EGF showed no significant benefit over unloaded scaffolds towards the healing of 
excisional porcine wounds [96]. These data highlight the importance of in vivo testing, as in vitro 
assays cannot fully recapitulate the complex environment of a wound.  
Not all scaffolds are formed by electrospinning. Modified chitosan was also used to 
synthesize porous foam dressings for release of neurotensin (NT) to modulate the inflammatory 
stage in diabetic wounds. The chitosan scaffolds delivering NT increased early wound closure 
dramatically compared to unloaded scaffolds by mitigating the acute inflammatory response and 
increasing collagen deposition by dermal fibroblasts [97]. 
1.3.3 Particles 
Nano- and microparticles are another highly studied type of drug delivery system which hold 
certain advantages over hydrogels and scaffolds. With respect to wound healing applications, 
particles may by injected by fine-gauge needle into the healthy tissue surrounding the wound so 
as not to complicate healing within the wound bed. They may also be tuned through numerous 
parameters to have complex release profiles unobtainable with gels and scaffolds [98, 99].  
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Poly(lactic-co-glycolic acid) (PLGA) is the most common polymer used to synthesize 
particles for controlled delivery. One rationale is that the lactic acid produced as the PLGA 
degrades may actively participate in the healing process, stimulating collagen synthesis and 
angiogenesis [100]. PLGA nanoparticles were developed to protect the activity of curcumin and 
release it over 8 days. When evaluated in full-thickness splinted excisional wounds in mice the 
combined effect of lactate and curucmin reduced the inflammatory response and enhanced 
angiogenesis and granulation tissue formation [101]. Similar nanoparticles were also used to 
release EGF albeit much more quickly, lasting only a day. Still, when applied to excisional 
wounds in diabetic rats the therapy induced the greatest number of proliferating cells and slightly 
accelerated wound closure compared to free EGF solution [102]. 
Particles have also been developed to deliver genes or plasmids. One example are 
biodegradable poly(β-amino esters) (PBAE) nanoparticles used to deliver plasmid Sonic 
hedgehog, a morphogen  known to play multiple roles in tissue regeneration. After intradermal 
injection of the particles at the periphery of mouse wounds, upregulation of multiple growth 
factors and greater neovascularization in the wounds was observed [103]. 
In a unique and interesting approach, nanoparticles of a silica, PEG, and chitosan 
composite were used to provide slow and sustained release of NO to wounds. NO is known to 
have both immunoregulatory and wound healing properties. The nanoparticles applied topically 
accelerated healing of both infected and uninfected mouse wounds [104, 105]. Furthermore they 
were directly compared to the common NO-donor, diethylenetriamine (DETA NONOate) and 
showed superior results in a mouse wound model of diabetes combined with immunodeficiency, 
which has significant clinical relevance [106]. 
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Nanoparticles need not necessarily be polymeric; in fact, lipids hold an advantage of 
rapid self-assembly without requiring organic solvents. One group developed two types, solid 
lipid nanoparticles (SLNs) and nanostructured lipid carriers (NLCs) for delivery of EGF. The 
loading efficiency of NLCs was greater than that of SLNs, as is common with encapsulating 
cargo within a shell versus entrapping it in a matrix. Both types of lipid particles delivering EGF 
significantly accelerated healing of full-thickness wounds in db/db mice, however four 
applications were necessary, possibly due to the inability of the vehicle to adequately sustain 
release [107].  
Particles are also easily incorporated within other carrier systems to augment their 
functionality. They may be used to extend release if the inherent rate is too quick, or to provide 
biphasic release kinetics. For example, a polyurethane scaffold embedded with gelatin-coated 
PLGA microparticles, each releasing PDGF, produced a quick burst followed by slow prolonged 
release [14]. Likewise, distinct release kinetics for multiple factors will be very important for 
certain applications [108]. Nanofiber composite scaffolds of chitosan and PEO were synthesized 
for fast release of VEGF and combined with nanoparticles providing slow sustained release of 
PDGF. Dual release resulted in fast closure of full-thickness wounds in rats, driven by an 
enhanced angiogenic response [109].  
In one notably elaborate delivery vehicle, VEGF and PDGF were placed in gelatin 
nanoparticles and combined with FGF-2 and EGF embedded in electrospun collagen and HA 
nanofibers for sustained release of 4 factors at once.  Accelerated wound closure, increased 
collagen deposition and improved angiogenesis were all observed when the scaffolds were 
implanted in excisional wounds on diabetic rats [110]. Complex scaffolds with their own 
functionality have also been developed to compliment the delivery of a single factor. For 
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example, an inner gelatin hydrogel layer for maintenance of a moist wound environment and 
containing FGF-2 microspheres was layered below an outer polyurethane membrane to protect 
the wound. This bi-layer scaffold proved effective at healing porcine full-thickness wounds 
[111].  
Gelatin microparticles delivering FGF-2 suspended in a gelatin hydrogel showed good 
results in a porcine pressure-induced decubiticus ulcer model [112]. In another approach, gelatin 
microspheres were conjugated to a catechol-type protease inhibitor, loaded with doxycycline, 
and incorporated into a collagen dressing [113]. Their ability to reduce MMP levels in the wound 
bed and prevent infection was evaluated in a bacteria-challenged excisional wound model in rats 
[114]. Finally, gelatin microparticles delivering FGF-2 were dispersed within a collagen sponge 
and enhanced angiogenesis and cell proliferation in a mouse model of pressure ulcers [115]. 
One group loaded chitosan microparticles with EGF and VEGF and suspended them in a 
dextran hydrogel for application to burn wounds. The therapy did show a beneficial effect in a 
rat burn wound model, however weekly applications were necessary, indicating that the release 
duration was too short [116]. Another group suspended PLGA nanoparticles delivering VEGF 
and FGF-2 in a composite hydrogel and applied it to full-thickness wounds on diabetic mice. 
This combined therapy led to improved wound closure compared to control scaffolds but not 
compared to the scaffold with free growth factors [117]. These results highlight some potential 
drawbacks of particulate delivery systems. Most require organic solvents which can reduce the 
bioactivity of fragile protein drugs significantly. Additionally, constant release rate is difficult to 
achieve because they inherently follow first-order kinetics due to changing surface area as the 
particles degrade [98]. 
 16 
1.3.4 Complexes and Conjugates 
A fourth type of delivery system comprises complexes and conjugates. Conjugates are typically 
formed by chemical bonds while complexes are typically formed by physical interactions. Both 
approaches seek to sequester soluble drugs in order to stabilize and extend their half-life or to 
provide targeting and facilitate their interactions with cell receptors. In one of the simplest 
examples of conjugation, PEG was attached to FGF-1 to improve its thermal and structural 
stability in vivo. In diabetic rat wounds, PEGylated FGF-1 led to complete wound closure 4 days 
faster than free FGF-1 and 7 days faster than control [118]. Complexes may also be used to 
improve skin permeation, of interest for wounds which have formed a protective scab or to treat 
deep tissue injury preceding a pressure ulcer. A low molecular weight version of protamine, a 
cation-rich nuclear protein, was developed to complex with the N-terminus of EGF. Protamine-
EGF complexes showed 11-fold greater transdermal penetration than free EGF and demonstrated 
efficacy in healing full-thickness wounds on both normal and diabetic mice [119] and in a mouse 
burn wound model [120]. 
Another very interesting approach involves engineering ECM mimetics, considering its 
significance in orchestrating the regenerative process [56, 121, 122]. One such approach is a 
synthetic peptide fragment of fibronectin containing its growth factor binding domain for protein 
loading, an integrin-binding domain to localize the complex to cells, and a factor XIIIa sequence 
for cross-linking to form a matrix to facilitate injection. The multi-functional recombinant 
fibronectin was applied for co-delivery of VEGF and PDGF to diabetic mouse wounds, where it 
induced angiogenesis and accelerated wound closure [123]. The same group used a similar 
approach to deliver the cytokine CXCL11 which, synergistic with fibronectin, promoted diabetic 
wound healing in db/db mice [124]. Along similar lines, vitronectin complexes with insulin-like 
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growth factors (IGFs) can enhance keratinocyte migration and protein synthesis [125], and 
similar effects were observed with EGF and FGF-2 [126]. In their first pre-clinical evaluation, 
vitronectin complexes of IGFs and EGF accelerated healing of partial-thickness burn wounds in 
pigs, although this approach did require multiple administrations per week [127]. To improve the 
clinical usefulness, HA was then added as a carrier system for vitronectin:GF complexes [128]. 
In a clinical pilot study, this therapy demonstrated convincing efficacy at re-epithelializing  
venous leg ulcers, and also showed promise for treating other types of chronic wounds [129]. 
These results provide strong evidence for consideration of the role of the ECM in growth factor 
signal transduction when designing controlled delivery vehicles.  
Another group designed polymer-growth factor conjugates using a “Polymer Masking-
UnMasking-Protein Therapy (PUMPT)”. They demonstrated that succinoylated dextrin 
conjugated to EGF can stabilize the protein until the polymer degrades at the target site and 
“unmasks” its bioactivity [130, 131]. The group went on to evaluate dextrin-EGF in full-
thickness diabetic mouse wounds and the therapy had marked success [132]. In another unique 
approach S-nitrosothiols (RNSOs) were grafted onto a polymer backbone and then interpolymer 
complexes were created to form a cross-linked polymer network. This vehicle provided sustained 
release of NO for at least 10 days and accelerated healing of excisional wounds in diabetic rats, 
although the mechanistic benefits were not explored [133]. 
The specificity of complexes and conjugates may be seen as a disadvantage because 
many cannot be used as a platform for delivery of different types of molecules. Because they are 
designed with a specific target in mind, the synthesis and optimization process can become time-
consuming. On the other hand, a specialized delivery vehicle will often lead to better outcomes 
compared to delivery with a generalized release platform.  
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1.3.5 Coacervates 
Coacervates are an interesting new class of drug delivery vehicles developed only recently for 
controlled release of proteins and small molecule drugs. Coacervates are nanometer-sized liquid 
droplets, held together and apart from their environment by hydrophobic forces [134]. As 
delivery vehicles, they feature rapid preparation by self-assembly not requiring organic solvents, 
and high loading capacity [135]. Preparation in aqueous solution is convenient and circumvents 
the risk of protein denaturation or residual organic solvents in conventional particle synthesis. 
Coacervates are also distinct from polymeric particles in their mechanical properties; they are 
soft and deformable which is particularly amenable to a wound environment where they may 
reside without impeding the massive influx of cells. This deformable nature allows for quick 
adsorption and spreading to coat polymeric scaffolds and provide drug release for tissue 
engineering applications [136]. Although they are a relatively young technology with just a 
decade’s worth of experimental validation, the advantages several coacervate systems have 
shown over conventional delivery methods bears much promise for their utility in the future 
[137].  
One well-described coacervate system is elastin-like peptides (ELPs). These are 
recombinant proteins which resemble the hydrophobic regions of tropoelastin which undergo 
spontaneous coacervation above a tunable transition temperature [138]. Fusion proteins 
containing ELPs and KGF were developed and self-assembled into coacervate particles at body 
temperature. A chronic wound model was performed using an insulin-resistant diabetic mouse 
strain, and the fusion peptide led to markedly enhanced granulation and re-epithelialization 
[139]. 
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A second coacervate system is a polycation:heparin complex which was developed 
specifically for the controlled delivery of heparin-binding growth factors [21, 140]. The growth 
factor is pre-bound to heparin, then a synthetic polycation is added which instantly forms liquid 
coacervate droplets by charge-based complexation. Within the coacervate the growth factor is 
protected from the proteolytic wound environment and its bioactivity upon release is enhanced 
by heparan sulfate preotoglycan-like interactions. This coacervate was utilized to sustain the 
release of heparin-binding epidermal growth factor (HB-EGF) with near zero-order release 
kinetics for at least 10 days. A single application of the HB-EGF coacervate to full-thickness 
excisional mouse wounds accelerated wound closure by enhancing wound granulation, re-
epithelialization, keratinocyte proliferation, and angiogenesis [141]. 
One drawback of coacervates is their relative instability in the body. They are held 
together by relatively weak interactions which may dissociate by large environmental changes in 
pH or ionic strength. However, these are typically stable within a particular tissue in the body. 
On the other hand, this responsiveness may also be used to build in stimuli-responsive 
specificity.  
1.3.6 Future goals 
A wide variety of biomaterial-based delivery systems exist for proteins, genes, and small 
molecule drugs with wound healing applications. Hydrogels, scaffolds, particles, complexes, and 
coacervates have each demonstrated success in numerous in vivo models and each may be 
optimal for a particular application or circumstance. However, wound healing is an extremely 
complex process and it is important to understand the etiology of each wound type and develop 
similarly complex delivery systems for individualized treatment. Towards this goal, it will be 
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necessary to combine different types of biomaterials to develop composite systems capable of 
delivering multiple factors with precise release kinetics.  
1.4 THE POTENTIAL OF COACERVATE SYSTEMS IN DRUG DELIVERY 
A complex coacervate is a liquid-liquid separation formed by electrostatic interactions between 
two polymers of opposite charge. Coacervates exist as spherical liquid droplets, often on the 
nanometer or micron scale in diameter, resembling an emulsion except that they do not 
necessarily contain stabilizing molecules such as surfactants. Coacervates have been investigated 
since the mid-20th century mostly within the context of food science research [134]. With the 
advancement in drug delivery, the use of coacervates as controlled delivery vehicles has started 
only recently. One particularly attractive feature of coacervates for drug delivery is their high 
loading capacity and the fact that they form by self-assembly in an aqueous medium [135]. Once 
encapsulated within the coacervate phase, labile proteins or drugs are separated and protected 
from the surrounding environment, thereby preserving their bioactivity. Compared to other 
common vehicles such as hydrogels and microparticles, coacervates form quickly and do not 
require organic solvents which could reduce protein drug retention and bioactivity. Finally, their 
size often enables coacervates to be applied via fine gauge needles, important for minimizing 
damage associated with injection. 
Several themes have become apparent among complex coacervates developed for drug 
delivery. One major theme is the incorporation of native extracellular matrix (ECM) proteins 
such as heparin, elastin, hyaluronic acid, and chondroitin sulfate. These approaches strategically 
employ the body’s own charged molecules as one or both components of the coacervate, most 
 21 
commonly the polyanion. Secondly is the slow and sustained manner of release of loaded cargos, 
avoiding burst release experienced with many other types of delivery systems. Thirdly, due to 
their reliance on charge-based interactions coacervates exist in dynamic equilibrium with their 
environment. They are therefore susceptible to disaggregation in response to increasing ionic 
concentrations of their environment which interfere with these interactions.  The consequences 
of these characteristics are well understood and can therefore be anticipated and even exploited 
to engineer coacervate drug carriers with precise design requirements.  
Below we exhibit several coacervate systems which have been developed for the delivery 
of small molecule drugs and proteins. Despite their apparent similarity with coacervate, charge-
based polyplexes for nucleic acid delivery [142] and lipid-based emulsion delivery systems [143] 
are thoroughly reviewed elsewhere and will therefore not be described here. 
1.4.1 Elastin-like peptides 
Elastin-like peptides (ELPs) were developed in the late 20th century [144], then further explored 
as drug delivery vehicles more recently [138]. ELPs are recombinant proteins designed to mimic 
the hydrophobic regions of tropoelastin. They consist of simple pentapeptide repeats, most 
commonly VPGXG, where X represents any amino acid except proline, termed the “guest 
residue”. ELPs exhibit an inverse temperature phase transition, aggregating to form a coacervate 
above their transition temperature (Tt) which is tunable based on the guest residue and ELP chain 
length [145].  
Drug delivery using ELPs has been focused on targeting and abolition of solid tumors 
[146]. One approach is local injection of ELPs with a Tt between room and body temperature, 
enabling in situ coacervation to form drug depots which slowly release their cargo. After intra-
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tumoral injection of radionuclide-conjugated ELPs, tumor regression was observed in more than 
two-thirds of the mice treated and the therapeutic effects lasted for at least 2 months [147]. A 
second approach is systemic injection of ELPs with a Tt between body temperature and 42 ˚C in 
combination with mild hyperthermia at the target tumor site. Local heating of the tumor, 
achieved clinically by methods such as ultrasound, increases extravasation of the ELPs and 
induces in situ coacervation. This method resulted in two-fold higher accumulation of 
doxorubicin-conjugated ELPs at the tumor site compared to non-heated tumors and even greater 
accumulation if multiple thermal cycles were applied [148, 149]. ELP coacervate has also 
demonstrated usefulness in tissue engineering applications as a viscous medium for delivery and 
differentiation of chondrocytes or progenitor cells [150, 151]. 
1.4.2 Carboxymethyl chitosan-based coacervates 
Carboxymethylation increases the water solubility of chitosan and the resulting carboxymethyl 
chitosan (CMC) has become a commonly studied polymer with a variety of applications, 
including drug delivery. The polyanionic nature of CMC enables its coacervation with 
positively-charged molecules via electrostatic interactions. This method was employed using 
unmodified chitosan as the polycation to deliver doxorubicin in an oral formulation that slowly 
released it within the GI tract, significantly increasing its intestinal absorption and bioavailability 
in the blood [152]. The group went on to encapsulate the coacervate beads within sodium 
alginate shells for further stabilization and protection in the low pH gastric environment [153].  
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1.4.3 Mussel adhesive proteins 
Another common coacervate system exploits the unique properties of charged proteins secreted 
by marine organisms such as tubeworms and mussels. These polyelectrolyte proteins undergo 
complex coacervation to produce a robust underwater adhesive which facilitates anchoring to a 
surface or cementing together sand and shell fragments. Recombinant mimics of these mussel 
adhesive proteins (MAPs) have been characterized and evaluated for numerous applications 
[154]. Of particular importance for drug delivery, coacervation of recombinant hybrid MAPs 
with hyaluronic acid (HA) creates micron-sized droplets that are stable for at least 8 days in 
phosphate-buffered saline [155]. Recombinant MAPs also retain their adhesive qualities after 
coacervation with HA, allowing their use as a device coating or easy integration into tissue 
engineered scaffolds [156]. Although these systems have yet to be used in a drug delivery 
setting, these explorations are anticipated in the near future.  
1.4.4 The future of coacervate delivery vehicles 
Compared with other drug delivery vehicles including micro- and nano-particles, liposomes, 
hydrogels and dendrimers, coacervate is a very recent development, with just over a decade of 
history.  Despite the short history, coacervate delivery vehicle as a class has already shown that: 
(1) it forms rapidly in water by self-assembly, (2) it can substantially improve the bioactivity of 
proteins in vitro and in vivo, (3) it readily coats a biomaterial surface either alone or combined 
with other molecules, (4) it can increase the efficacy of cell therapy, and (5) targeting is feasible. 
Self-assembly in water and affinity to proteins that significantly reduce protein denaturation and 
burst release make coacervate a rational choice for controlled release of proteins and peptides. 
 24 
Ionic coacervates can be less stable compared with conventional drug delivery vehicles in 
biological fluids because of their ionic nature, and this needs to be addressed for a systemic 
delivery route when the coacervate will be carried by blood. To this end, much can be borrowed 
from strategies for stabilization of liposomes. Furthermore, active targeting of a specific tissue or 
pathology (e.g. cancer, infarction, or inflammation) will greatly expand the utility of this new 
class of drug delivery vehicles. Other future growth areas are “control” over release kinetics 
including stimulus-responsive release and external guidance of the coacervate post-injection.  In 
all, we anticipate that coacervate will evolve into a versatile tool for controlled drug delivery in 
the near future and a likely catalyst for the “big bang” of this field will be a successful clinical 
translation of any coacervate vehicle.  
1.5 A POLYCATION:HEPARIN COACERVATE DELIVERY VEHICLE 
Our lab previously developed a coacervate delivery system which utilizes heparin to first bind 
one or more heparin-binding proteins, including numerous growth factors, cytokines, and 
morphogens [157]. A synthetic polycation  containing arginine [158] as the positive charge-
bearer is then introduced to interact with the highly-sulfated heparin by polyvalent charge 
attraction. A complex coacervate instantly forms with droplet sizes range from 0.1-10 µm in 
diameter, dependent on the loaded protein and the ionic environment. The strong, specific 
interaction between heparin and heparin-binding proteins results in very high loading efficiency 
of this coacervate, often greater than 99%. The release rate is influenced by multiple factors, 
including the heparin-binding affinity of the protein of interest, the net charge of the coacervate, 
and the polycation molecular weight, charge density, and biodegradation rate [21, 159].  
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One significant advantage of this coacervate system is owed to pre-conjugation of the growth 
factors to heparin which potentiates their bioactivities by mimicking the way that ECM 
proteoglycans present these factors to cell receptors [21, 159]. In one instance, a single injection 
of heparin-based coacervate delivering fibroblast growth factor-2 (FGF-2) induced stable 
angiogenesis subcutaneously [20]; a similar benefit was observed after injection into the 
infarcted myocardium which resulted in improved cardiac function [160]. Another advantage of 
this controlled release system is its simple incorporation into tissue engineering scaffolds by 
adsorption. This technique was recently employed to recruit progenitor cells into a porous 
polymer graft by slowly releasing the stem cell trafficking chemokine, stromal cell-derived 
factor-1α (SDF-1 α) [136]. 
1.6 SPECIFIC AIMS 
The central hypothesis of this research is that controlled growth factor delivery with a 
polycation:heparin coacervate can stimulate tissue regeneration in the clinically-relevant context 
of skin wound healing, cardiac repair, and bone regeneration. Our preliminary results and the 
current literature on growth factor signaling pathways supports the use of the following growth 
factors for respective indications: Heparin-binding EGF-like growth factor (HB-EGF) for skin 
wound healing [141, 161, 162], Sonic hedgehog (Shh) morphogen for cardiac repair [163-166], 
and bone morphogenetic protein-2 (BMP-2) for stimulation of muscle-derived stem cells 
(MDSCs) to regenerate bone defects [167-169]. Towards our central hypothesis, I tested the 
efficacy of coacervate-based controlled delivery of each of these factors in a clinically-relevant 
animal model, outlined in the following four Specific Aims: 
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Specific Aim 1:    Develop a coacervate delivery vehicle with tunable release kinetics. 
A lysine-based polycation was designed to interact with heparin and self-assemble to a 
coacervate structure. The cytocompatibility of the polycation was evaluated and its loading 
efficiency and tunable release rate described. Finally, it was demonstrated that the coacervate 
may be adsorbed onto polymeric scaffolds to provide integration of controlled release with tissue 
engineering scaffolds.  
Specific Aim 2:   Evaluate the efficacy of controlled delivery of HB-EGF to 
accelerate dermal wound healing.  Growth factor therapy has the potential to accelerate the 
healing of acute wounds such as surgical incisions, and chronic wounds such as diabetic ulcers. 
The stimulatory effects of HB-EGF coacervate on the proliferation and migration processes of 
human dermal cells were first evaluated using in vitro assays. Full-thickness skin wounds were 
then created on both normal and genetically-diabetic mice to test the in vivo efficacy of this 
therapy and elucidate the mechanisms of improved healing.  
Specific Aim 3:    Investigate the controlled delivery of Shh morphogen to promote 
cardiac repair following myocardial infarction.  Heart failure resulting from myocardial 
infarction is a leading cause of death and morbidity worldwide [170]. Shh morphogen activates 
multiple pro-regenerative processes, which were first studied in vitro using cardiac myocytes and 
fibroblasts. The Shh coacervate was then loaded into a polyethylene glycol (PEG) hydrogel to 
prevent its leakage following injection into the pulsating heart muscle. Myocardial infarction was 
induced in rats by ligation of the coronary artery and the hydrogel was injected within the 
ischemic zone and evaluated over 4 weeks.  
 Specific Aim 4:  Assess the contribution of controlled delivery of BMP-2 towards 
improving MDSC therapy for bone defect regeneration.  Congenital or trauma-induced bone 
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injuries currently lack a good clinical solution [171]. We utilize BMP-2 delivered by the 
coacervate to stimulate the osteogenic differentiation of MDSCs in situ. We first tested the in 
vitro cytotoxicity and bioactivity of the BMP2 coacervate on MDSCs. Next we elucidated the 
potential of this co-therapy to form ectopic bone by injection into the mouse quadriceps muscle 
pocket where the signals to produce bone are absent. Finally, to evaluate the translational 
potential of this therapy we used human MDSCs in a critical-sized cranial defect model using 
immunodeficient mice and directly compared to a gene therapy approach. 
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2.0  DEVELOPMENT OF A POLYCATION:HEPARIN VEHICLE WITH TUNABLE 
RELEASE KINETICS 
Polycations have high potential as carriers of proteins and genetic material. However, poor 
control over release rate and safety issues currently limit their use as delivery vehicles. Here we 
introduce a new lysine-based polycation, poly(ethylene lysinylaspartate diglyceride) (PELD) 
which exhibits high cytocompatibility. PELD self-assembles with the biological polyanion 
heparin into a coacervate that incorporates proteins with high loading efficiency. Coacervates of 
varying surface charge were obtained by simple alteration of the PELD:heparin ratio and resulted 
in diverse release profiles of the model protein bovine serum albumin. Therefore, coacervate 
charge represents a direct means of control over release rate and duration. The PELD coacervate 
also rapidly adsorbed onto a porous polymeric scaffold, demonstrating potential use in tissue 
engineering applications. This coacervate represents a safe and tunable protein delivery system 
for biomedical applications. 
2.1 INTRODUCTION 
Polycations have high potential as carriers of proteins and genetic material. Chitosan and 
polyethylenimine (PEI) are two polycations commonly used in biomedical applications including 
non-viral gene delivery [172-175], vaccine administration [176, 177], and delivery of peptides 
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[178, 179]. However, safety risks associated with cytotoxicity and the accumulation of 
nanoparticles following delivery seriously limit their potential [180, 181]. Poly(L-lysine) (PLL) 
has also been widely investigated as a delivery vehicle for proteins and DNA [182-185], 
however PLL has similar biocompatibility issues as PEI [186, 187]. A synthetic polycation with 
good biocompatibility and controllable release rate would be highly beneficial for biomedical 
applications involving protein or gene therapy. 
We have previously reported the synthesis of an arginine-based polycation, poly(ethylene 
argininylaspartate diglyceride) (PEAD), designed to complex with heparin to form a delivery 
matrix for heparin-binding growth factors [158]. PEAD:heparin self-assembles to form a 
coacervate, an assortment of organic molecules held together by polyvalent charge attraction and 
separated from the aqueous phase. We have demonstrated the use of this coacervate to deliver 
several factors for stimulating angiogenesis [20], accelerating cutaneous wound-healing [141], 
and improving heart function post-myocardial infarction [160, 166]. In all cases the coacervate 
showed high loading efficiency, protection from degradation, sustained release over time, and 
enhanced bioactivity compared to the growth factor in free-form. Having demonstrated that the 
coacervate satisfies the necessary functions of a delivery vehicle, we now address controllability 
of release rate by modification of the polycation and the coacervate composition. 
The polyvalent and ionic nature of the coacervate makes modification of the charge 
density of the polycation one of the simplest ways to control release rate. Adjusting the 
polycation:heparin ratio in the coacervate is another simple way. The polycation and growth 
factor compete for ionic interaction with heparin; thus a coacervate with greater polycation 
content will compete more, resulting in faster growth factor release, while lower polycation 
content will slow release. We first attempted to control growth factor release using this approach 
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with PEAD, however the charge density of this polycation was too large. A very small decrease 
in the PEAD:heparin mass ratio led to such a large drop in the overall coacervate charge that the 
growth factor did not release (Fig. 3). Therefore our rationale for the development of a new 
polycation was that a polycation of slightly weaker charge density may allow for improved 
control over release rate.  
  
 
 
Figure 3.  Effect of PEAD:heparin on BSA release.    The PEAD:heparin mass ratio was varied and the 
release of bovine serum albumin (BSA) tracked over 21 days. 
 
 
 
Here we report a new polycation, poly(ethylene lysinylaspartate diglyceride) (PELD), 
with lysine as the source of positive charge instead of arginine. PEAD has high biocompatibility 
[158], and here we demonstrate that the same design principle applies to lysine, thus PELD also 
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has excellent biocompatibility. We describe the synthesis and characterization of PELD and its 
usefulness for controlled release.  
2.2 MATERIALS AND METHODS 
2.2.1 Materials 
Ethylene glycol diglycidyl ether (EGDE) and trifluoroacetic acid (TFA) (TCI America, Portland, 
OR), t-BOC aspartic acid (BOC-Asp-OH) and t-BOC lysine (BOC-Lys) (Bachem, Torrence, 
CA), dimethylforamide (DMF), dichloromethane (DCM) and tetra-n-butylammonium bromide 
(TBAB) (Acros Organics, Geel, Belgium), dicyclohexylcarbodiimide (DCC) and N-
hydroxysuccinimide (NHS) (Alfa Aesar, Ward Hill, MA), 4-dimethylaminopyridine (DMAP) 
(Avocado Research Chemicals, Lancaster, UK), and polyethleneimine (PEI; MW=50-100 kDa) 
(MP Biomedicals, Santa Ana, CA) were used as received. Heparin Sodium USP (MW=16 kDa; 
Scientific Protein Labs, Waunakee, WI), fluorescein (Aldrich Chemical Co, Milwaukee, WI), 
bovine serum albumin (BSA) (Millipore, Billerica, MA), and poly(D,L-lactide-co-glycolide) 
50:50 (PLGA) (Lakeshore Biomaterials, Birmingham, AL) were also used as received. 
2.2.2 Synthesis of PELD 
The intermediate, poly(ethylene aspartate diglyceride) (PED) was synthesized as previously 
described [158]. Briefly, EGDE (1.00 g) was combined with BOC-Asp-OH (1.34 g) and TBAB 
(5 mg) and dissolved in 0.6 ml DMF. The mixture was maintained at 120⁰C under N2 for 20 m in 
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a microwave synthesizer (Biotage, Uppsala, Sweden). DMF was evaporated under reduced 
pressure and TBAB was removed by multiple precipitations in diethyl ether. t-BOC was 
removed by stirring product in 4:1 DCM:TFA for 2 h. t-BOC lysine was conjugated to PED by 
DCC/NHS coupling. Briefly, BOC-Lys (0.692 g), NHS (0.323 g), DCC (0.753 g), and DMAP (5 
mg) were dissolved in 5 ml DMF. PED (0.864 g) was dissolved in 5 ml DMF in a separate vial. 
The two vials were then combined and stirred under N2 for 24 h. An insoluble dicyclohexylurea 
byproduct formed and was removed by filtration at 0.22 μm. Finally, t-BOC was removed by 
stirring in pure TFA for 2 h and the product was purified by multiple precipitations in diethyl 
ether and then ethyl acetate. 
2.2.3 Characterization of PELD 
1H NMR was performed with a Biospin Avance NMR spectrometer (Bruker, Billerica, MA) 
using deuterium oxide (D2O) solvent. The Fourier transformed infrared (FTIR) spectrum was 
recorded using a Nicolet IR-100 spectrometer (Thermo, Waltham, MA). Differential scanning 
calorimetry (DSC) was performed under nitrogen gas at a heating rate of 10°C/min using a Q200 
DSC (TA Instruments, New Castle, DE). Glass transition temperature (Tg) was determined using 
Universal Analysis 2000 software (TA Instruments) as the middle of the glass transition. Gel 
permeation chromatography (GPC) was performed on a Viscotek VE2001 system equipped with 
a 270 Dual Detector (differential refractive index and right angle light scattering) (Malvern 
Instruments, Westborough, MA). Two GRAM columns of 30 Å and 1,000 Å porosities (PSS, 
Warwick, RI) and dimethylacetamide containing 3 g/L lithium bromide and 6 ml/L acetic acid 
were used as the stationary and mobile phases, respectively, and results were compared to 
polystyrene standards for calibration. 
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2.2.4 Preparation of polycation:heparin coacervates 
PEAD, PELD and heparin were each dissolved in 0.9 % saline and 0.22 μm filter-sterilized. 
Addition of either polycation to heparin immediately induced self-assembly of the coacervate, 
causing the complex to phase separate, visible as a turbid solution. 
2.2.5 Zeta potential and dynamic light scattering (DLS) measurements 
PELD and heparin were dissolved in DI water at 10 mg/ml and 1 mg/ml, respectively, then 
combined at PELD:heparin mass ratios of 2.5, 5, 7.5, 10, 12.5, and 15. Each coacervate solution 
was diluted to a 1 ml total volume with DI water. Zeta potential and particle size (hydrodynamic 
diameter) were both measured using a Zetasizer Nano ZS (Malvern, Westborough, MA).10-20 
readings were taken for each mass ratio and averaged.  
2.2.6 Fluorescent imaging of PELD coacervates 
PELD and heparin were dissolved in DI water at 10 mg/ml and fluorescein at 10 μg/ml. 10 μl 
fluorescein was mixed with heparin first and then PELD was added  to form coacervates with 
PELD:heparin mass ratios of 5, 10, and 15. The total mass of coacervate (mPELD+mheparin) was 1 
mg for each, prepared in 0.1 ml water. The coacervates were added to a 96-well plate and imaged 
immediately using a Nikon Eclipse Ti fluorescent microscope (Nikon Instruments, Melville, 
NY).  
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2.2.7 Cytotoxicity assay 
PEAD was synthesized as previously described [158]. 5x104 NIH 3T3 fibroblasts were seeded 
per well in a 96-well plate and cultured for 12 h at 37⁰C/ 5% CO2 in DMEM containing 10% 
FBS and 1% penicillin/streptomycin. Media was then removed and culture media containing 
PEAD, PELD or PEI at various concentrations (10, 1, 0.1, 0.01 mg/ml) was added to 4 wells per 
group. After 24 h cells were washed once with DPBS and cell viability was assessed using 
Live/Dead Assay (Molecular Probes, Eugene, OR) following manufacturer’s instructions. 
Results were normalized and compared to a control group which was not exposed to a 
polycation. 
2.2.8 BSA release assay 
PELD and heparin were each dissolved in 0.9% saline at 10 mg/ml. Heparin was initially 
combined with 500 μg BSA, then PELD was added to form mass ratios of 6, 8, and 10, 
corresponding to zeta potentials of approximately -10, -5, and 0 mV, respectively. Tubes were 
stored at 37⁰C under shaking conditions and after 0, 1, 3, 7, 14, and 21 days, tubes were 
centrifuged at 12,000 x g for 5 min and the supernatant removed and frozen at -20C. After all 
timepoints were collected, BSA concentration was determined using the Pierce 660 nm Protein 
Assay (Thermo). In order to account for protein content of the polycations and heparin in the 
release fractions, results were normalized to an assay performed identically but without BSA.  
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2.2.9 Coacervate adsorption to polymer scaffolds 
Porous PLGA scaffolds prepared by salt-leaching technique were synthesized as previously 
described [188]. The scaffolds were 1 mm thick and 5 mm in diameter with a 75-150 µm pore 
size. PELD and heparin were dissolved in deionized water at 5 mg/ml and combined at a 10:1 
PELD:heparin mass ratio for maximal turbidity at charge neutrality. 1.2 ml coacervate was added 
to a glass vial and stirred to prevent settling of the coacervate by gravity. 50 µl coacervate was 
removed to a cuvette and optical density was read using a spectrophotometer (Biotek, Winooski, 
VT). PLGA scaffolds were then added to three separate vials and the coacervate was sampled 
and optical density read in similar fashion every 5 min. Three vials that did not receive any 
scaffold were used as the control. Digital images of the PELD coacervate-coated PLGA scaffold 
were taken at the endpoint, next to a bare PLGA scaffold.  
2.2.10 Scanning electron microscopy 
PELD and heparin were dissolved in deionized water at 10 mg/ml and combined at a 10:1 
PELD:heparin mass ratio to form the coacervate. For coacervate imaging alone 500 μl 
coacervate was pipetted directly onto an aluminum stub. For PLGA scaffold coating, scaffolds 
were submerged in 1 ml coacervate and soaked for 5 min, then mounted on aluminum stubs. 
Uncoated scaffolds from the same batch were also prepared. All samples were frozen and 
lyophilized overnight. Samples were sputter coated with gold at a 3.5 nm thickness and imaged 
using a JEOL JSM-633 OF scanning electron microscope (JEOL USA, Peabody, MA). 
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2.2.11 Statistical analysis 
Statistical analysis was performed using SPSS 16.0 software (SPSS Inc, Chicago, IL). 
Data was tested for normality and equal variance before analysis. Statistical differences were 
calculated using one-way analysis of variance (ANOVA) followed by Tukey’s post-hoc testing. 
2.3 RESULTS AND DISCUSSION 
2.3.1 PELD synthesis and characterization 
The intermediate involved in PELD synthesis, PED, is also used in PEAD synthesis, as 
previously reported [158]. Briefly, PED is formed by polycondensation of a 1:1 molar ratio of t-
BOC aspartic acid and EGDE, followed by removal of the BOC protecting group (Fig. 4a). t-
BOC lysine is then conjugated and subsequently de-protected to form the final product. During 
the conjugation step, t-BOC lysine is activated by DCC and may then react intermolecularly as 
its contains one unprotected primary amine. PED is added immediately following activation to 
limit the amount of poly-lysine that forms before conjugation. This appears to have little effect 
on the functionality of the polycation for complexation with heparin; however, lysine with both 
amine groups protected may be used in the future for a more homogeneous product. Purification 
by repeated precipitations removes solvents and byproducts until no impurity peaks are observed 
on the 1H NMR spectrum. PELD was analyzed by 1H NMR for chemical shifts distinctive of its 
structure (Fig. 4b). Protons in the ethylene glycol backbone produced shifts at δ4.1 and 4.4 and a 
multiplet between δ3.4 and 3.9. Shifts between δ1.2 and 1.8 correspond to the aliphatic tail of 
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lysine. FTIR analysis of PELD shows absorbance around 1665 cm-1 resulting from ester bonds 
and in the 3000-3500 cm-1 range due to amide bonds and free hydroxyl groups (Fig. 4c). PELD 
had a Tg of 51.92 °C, and no crystallization was observed between -50 °C and 150 °C (Fig. 4d). 
GPC analysis indicated that PELD had a molecular weight (Mp) of approximately 3.5 kDa. 
 
 
 
Figure 4. Synthesis and characterization of PELD and PELD:heparin coacervate   a) The intermediate 
PED was synthesized by polycondensation of EGDE and aspartic acid. PELD was formed by conjugation of t-BOC 
lysine to aspartic acid in PED. Groups producing characteristic chemical shifts in the 1H NMR spectrum are 
indicated. b) 1H NMR spectrum of PELD shows signals characteristic of lysine and the backbone comprised of 
glycerol and aspartic acid. The D2O is observed at δ4.8. c) FTIR spectrum of PELD shows ester stretches at 1665 
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cm-1 and weak amide and hydroxyl stretches near 3000 cm-1. d) DSC thermogram indicates a glass transition 
temperature of 51.92°C. e) Scanning electron micrograph of lyophilized PELD:heparin coacervate displaying both 
ribbon-like sheets and globular domains. Scale bar = 10μm. 
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2.3.2  Characterization of PELD:heparin coacervates When combined with polyanions such 
as heparin, PELD self-assembles into a coacervate. Coacervation is a liquid-liquid phase 
separation analogous to an emulsion except that the coacervate phase still contains water [135]. 
The PELD:heparin coacervate is visible as a turbid solution. The morphology of the PELD 
coacervate was observed by scanning electron microscopy (Fig. 2e) and reveals both ribbon-like 
sheets and fibers, and globular structures. The ribbon-like structures are on the micron scale and 
highly variable in size, while most globular beads are 1-5 μm. A number of different 
PELD:heparin mass ratios ranging from 2.5 to 15 were further characterized. Zeta potential, a 
measure of the surface charge on a colloidal system, was analyzed first. As expected, a low 
PELD:heparin ratio yielded an overall negative surface charge, indicating an excess of anionic 
heparin (Fig. 5a). As the mass ratio increased, so did the zeta potential, reaching an overall 
neutral charge at a mass ratio of approximately 10. This indicates that heparin, the most 
negatively charged biomolecule, has approximately 10-fold greater charge density per unit mass 
compared to PELD. At mass ratios above 10, excess PELD molecules exist and create a positive 
surface charge. Zeta potential is also commonly used to estimate the stability of a colloidal 
system. Large positive or negative zeta potentials (generally +30 or -30 mV) indicate that the 
particles will tend to repel each other, while particles with low zeta potentials have little force to 
prevent aggregation. 
The hydrodynamic diameter, or particle size, was also observed using dynamic light scattering 
(DLS) to assess how the PELD:heparin mass ratio and resultant surface charge affects the 
coacervate droplet size. The smallest droplet size was observed was 214 nm at a mass ratio of 2.5 
and the largest was 1208 nm at a mass ratio of 7.5 (Fig. 5b). In general, large droplet sizes were 
observed around a mass ratio of 10, where the charge of the coacervate was near its isoelectric 
 40 
point. As the mass ratio was adjusted, and the zeta potential deviated from zero, the droplet size 
decreased. This is likely an effect of coacervate aggregation, further elucidated by polydispersity 
measurements. 
Polydispersity index (PDI) in DLS measurements is calculated from the cumulants 
analysis of the DLS intensity autocorrelation function. It is arbitrarily scaled to a maximum value 
of 1 and values less than 0.2 are typically considered monodisperse while values greater than 0.7 
are considered highly polydisperse. Coacervates bearing the highest surface charge (mass ratios 
of 2.5 and 15) were monodisperse (Fig. 5b). However, as surface charge approaches neutrality 
the repulsion force between coacervate droplets decrease and aggregations form more readily. 
We also expect the size of aggregations to vary, thereby increasing the PDI. Indeed, we observed 
that PDI tended to increase as the coacervate surface charge approached neutrality with a 
maximal PDI of 1 at a mass ratio of 10.  
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Figure 5. Zeta potential and hydrodynamic diameter of PELD:heparin coacervates   PELD was 
combined with heparin at different mass ratios to form coacervates. a) Zeta potential measurements reveal surface 
charge of coacervates, with an isoelectric point (charge neutrality) at a mass ratio of 10. b) DLS measurements of 
hydrodynamic diameter and polydispersity of the coacervates. Hydrodynamic diameter represents the average size 
of the coacervate droplets in water. Polydispersity index (PDI) is arbitrarily limited to a maximum value of 1 with 
values ≤ 0.2 being considered monodisperse and values ≥ 0.7 indicating high polydispersity. 
 
 
Mass ratios of 5 (negative), 10 (neutral), and 15 (positive) were selected for fluorescent 
imaging. Fluorescein, a small, charged dye, was added to the heparin solution and became 
incorporated into the coacervate upon addition of PELD. Droplets ranging from < 1 μm to 
approximately 5 μm in diameter were observed in the negatively- and positively-charged 
coacervates, which appeared similar in size and distribution (Fig. 6). This correlates well with 
our DLS results with the droplets > 1 μm representing aggregates which lead to the recorded 
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polydispersity. The neutral coacervate had droplets ranging from 1-10 μm and was very 
polydisperse, as observed with DLS. Images were taken immediately after coacervation, 
therefore aggregation likely occurs more quickly in neutral coacervates. 
 
 
 
Figure 6. Fluorescent imaging of coacervates.Fluorescein, a charged fluorescent dye was incorporated 
into the coacervate to enable imaging by fluorescent microscopy. 10x magnification images of coacervates with 
PELD:heparin mass ratios of a) 5, b) 10, and c) 15. d-f) High magnification (40x) images of a-c, respectively. Scale 
bars=100 μm. 
 
2.3.3 PELD cytocompatibility 
Polycations typically carry high cytotoxicity, making them unsuitable in many translational 
applications.[189] Development of a biocompatible polycation which can deliver growth factors 
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without affecting cell response itself is of high importance. We tested the cytocompatibility of 
PELD using an established method for polycations with the fibroblast cell line, NIH 3T3.[190, 
191] We compared PELD to polyethyleneimine (PEI), a common polycation used in cell culture 
and as a polymer transfectant for non-viral gene delivery [192, 193]. We also used PEAD as a 
positive control as we have previously shown it to be highly biocompatible both in vitro and in 
vivo [158]. At concentrations up to 10 mg/ml PELD had no effect on cell viability compared to 
PEAD (Fig. 7). Conversely, PEI induced a significant reduction in fibroblast viability at all 
concentrations, even as low as 0.01 mg/ml, compared to both PEAD and PELD. This toxicity of 
PEI has been well documented previously and exemplifies a major limitation of many 
polycations in scientific research [182]. These results indicate that PELD displays no in vitro 
cytotoxicity issues in a range of concentrations that are physiologically relevant, considering the 
dilution when applied in the body. Considering the biocompatibility of PEAD [158] it is 
unsurprising that utilizing the same design principle for lysine results in a lysine-based 
polycation that also has excellent biocompatibility. 
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Figure 7. Polycation cytotoxicity.   NIH3T3 fibroblasts were exposed to PEAD, PELD, or PEI dissolved 
in culture media at 0.01, 0.1, 1, or 10 mg/ml. Cell viability was measured after 24 hours by Live/Dead assay. 
*p<0.01 compared to both PEAD and PELD groups. 
 
2.3.4 Controlled release from PELD coacervates 
The high cytocompatibility of PELD warranted further investigation of its suitability for 
controlled release of biomolecules. Heparin-binding sites often contain multiple cationic amino 
acids, rendering high positive charge density which interacts with the many sulfate groups of 
heparin.[194] Therefore PELD competes with growth factors and other proteins for binding to 
heparin, and thus positively-charged coacervates exhibit poor loading efficiency (data not 
shown). Only coacervates with negative zeta potential were investigated for release 
characteristics. We tested the loading and release of bovine serum albumin (BSA) from 
PELD:heparin coacervates of three different mass ratios over 21 days. BSA is commonly used as 
a model protein in drug delivery research and it also binds to heparin with a kd of 4.3 µM [195]. 
Observations common among all coacervates were high loading efficiencies of greater than 95%, 
low initial burst release, and sustained release thereafter through the end of the experiment 
(Figure 8). A direct relationship between charge and release rate was observed with a more 
 45 
negative charge inducing a slower release of BSA from the coacervate. Total release after 21 
days ranged from 17.4% to 58.8% for the -10 mV and 0 mV coacervates, respectively, with the -
5 mV coacervate displaying an intermediate total release. We expect that multiple mechanisms 
play a role in the release of biomolecules: degradation of the polycation, as has been 
demonstrated with PEAD and similar polycations [158, 159], dissociation of the coacervate in an 
ionic environment, and competition for heparin between the polycation and heparin-binding 
proteins. The dependence of release on charge supports the participation of the last mechanism.  
These data demonstrate that a high degree of control over release can be obtained by simply 
altering the PELD:heparin mass ratio of the coacervate. 
 
 
 
Figure 8. BSA release from coacervates.  PELD:heparin mass ratios of 10, 8, and 6 were used which 
correspond to zeta potentials of approximately 0, -5, and -10 mV, respectively. Each coacervate was loaded with 500 
μg BSA and release was quantified on days 0, 1, 3, 7, 14, and 21 by total protein assay. 
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2.3.5 Coacervate coating of polymeric scaffolds 
The value of a controlled release vehicle for many tissue engineering approaches will hinge on 
its ability to coat a polymeric scaffold. The coacervate is highly charged and therefore interacts 
by Coulombic forces with polymers bearing surface charge. It also contains many functional 
groups such as hydroxyl groups on PEAD which may form hydrogen bonds with polarized 
materials. Finally, the coacervate may participate in hydrophobic interactions with non-wetting 
surfaces as it is phase-separated from water.  
We next tested the ability of the coacervate to adsorb to a porous poly(lactic-co-glycolic 
acid) (PLGA) disk as a model polymeric scaffold. When the turbid coacervate solution was 
exposed to the disk the optical density dropped rapidly (Fig. 9a). The change in optical density 
was directly proportional to the fraction of coacervate removed from the solution and adsorbed to 
the scaffold. The coacervate adsorbed rapidly and after 15 minutes reached a plateau at maximal 
fractional adsorption. Coacervate alone with no scaffold served as a control, and showed no 
significant change in optical density throughout the course of the experiment. After 30 minutes, 
coacervate-coated scaffolds were a yellow-orange color, similar to the color of PELD (Fig. 9b).   
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Figure 9. Adsorption of PELD coacervate to polymer scaffolds.   PELD coacervate was prepared in 
water and then porous PLGA scaffolds were added. a) Coacervate adsorption to the scaffold was measured as a 
fractional change in optical density. A control coacervate solution did not receive a scaffold. b) PELD coacervate-
coated scaffold (right) next to a bare PLGA scaffold (left) at the endpoint of the experiment. Ruler units are 1mm.  
 
 
Coated and uncoated PLGA scaffolds were further analyzed by scanning electron 
microscopy. The coacervate was clearly observable as a thin network which covered the surface 
of the PLGA material and also spanned some pores with spider web-like morphology (Fig. 10). 
However, the coating does not occlude the pores, allowing space for cells to infiltrate the 
scaffold. There is also coacervate clearly visible within the pores of the scaffold, indicating that 
coacervate penetrated beyond the scaffold outer surface. This may be important for forming a 
chemokine gradient which extends into the scaffold for recruitment of cells. These data suggest 
that the coacervate delivery vehicle can be quickly and easily adsorbed onto polymeric tissue 
 48 
engineering scaffolds in aqueous solution to provide sustained release of heparin-binding growth 
factors or cytokines. 
 
 
 
Figure 10. Scanning electron micrographs of PELD coacervate adsorbed to scaffolds.  PLGA scaffolds 
with a 75-150 µm pore size were prepared by salt-leaching method and imaged by SEM. a) Uncoated PLGA 
scaffold (150x magnification). b) Coated PLGA scaffold, submerged in PELD coacervate solution in water for 5 
minutes, then lyophilized and imaged (150x magnification). c-d) High magnification (500x) SEM images of the 
indicated areas of a and b, respectively. All scale bars = 100μm. 
 
2.4 CONCLUSIONS 
We designed a lysine-based polycation to interact polyvalently with intact heparin and 
spontaneously form a coacervate in aqueous solutions. Compared to the commonly used 
polycation PEI, PELD displayed significantly better cytocompatibility. Loading and release of 
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BSA was tunable based on the PELD:heparin ratio of the coacervate. Finally, rapid adsorption of 
the coacervate onto polymeric scaffolds in water provides a simple means to integrate controlled 
release of biomolecules with tissue engineering scaffolds. These results suggest wide 
applicability of this polycation for controlled and sustained delivery of heparin-binding proteins. 
In the future, release rate and duration may be selected for specific growth factors on an 
application-specific basis. 
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3.0  CONTROLLED DELIVERY OF HB-EGF TO ACCELERATE DERMAL 
WOUND HEALING 
 
3.1 INTRODUCTION – NORMAL WOUND HEALING 
Dermal injury remains one of the most prevalent and economically burdensome healthcare issues 
in the world. In the US alone there are more than 100 million acute wounds annually, including 
surgical incisions, trauma, and burns [196]. Current wound management requires frequent 
dressing changes and patients are at constant risk of infection until the skin regains its barrier 
function. In chronic wounds, a variety of underlying detriments, including pressure, insufficient 
blood flow, and edema, prevents healing from occurring without proactive treatment [197]. 
Current treatment options are limited, costly, and inefficient. As a result, the development of new 
therapeutics is necessary to satisfy the clinical need. 
Growth factor therapies hold tremendous potential to address the shortcomings of current 
wound care modalities [198, 199]. Growth factors act as critical extracellular cues that 
orchestrate the wound healing process; supply of exogenous growth factors may therefore induce 
faster re-epithelialization, leading to reduced risk of infection and shorter inpatient stays. In cases 
of chronic wounds, growth factors may provide the necessary stimuli to induce wound closure 
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that is otherwise unlikely to occur [200]. Several important growth factors involved in the wound 
healing process are from the epidermal growth factor (EGF), platelet-derived growth factor 
(PDGF), and transforming growth factor-β (TGF-β) families.  Heparin-binding EGF-like growth 
factor (HB-EGF), although less studied, is present in both human and porcine wound fluid [201, 
202], and is a potent stimulator of keratinocyte proliferation and migration [203, 204]. HB-EGF 
has been shown to have mitogenic effects on fibroblasts [201, 205], and may therefore be 
involved in the formation of granulation tissues. Lastly, HB-EGF also plays a role in 
angiogenesis during wound healing [206, 207]. Clearly, HB-EGF acts as a versatile regulator of 
wound healing and would be highly beneficial as a regenerative therapeutic. 
Provision of exogenous growth factors can accelerate wound healing; however they must 
be applied in a sustained and localized fashion to be effective. This is due to short growth factor 
half-lives, rapid dilution in the body, and undesirable effects at high systemic levels [208]. Our 
group has developed a controlled delivery system based on intact heparin, a highly-sulfated 
glycosaminoglycan with similar functionality to the extracellular matrix (ECM)-derived 
proteoglycan, heparan sulfate. Heparin and heparan sulfate bind many growth factors with high 
affinity, extend their half-lives by protection from proteolytic degradation, and increase their 
bioactivity [209, 210]. To keep the water-soluble heparin:growth factor complex localized to the 
site of application, a synthetic polycation, poly(ethylene argininylaspartate diglyceride) (PEAD), 
was designed to interact with heparin through polyvalent charge attraction, forming a growth 
factor-containing coacervate [21]. In this simple delivery system, incorporated growth factors are 
separated from the aqueous environment in the oil phase of the coacervate, further protecting 
them from degradation. This delivery platform is capable of controlling the release of heparin-
binding growth factors and has been used to successfully deliver FGF2 to stimulate therapeutic 
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angiogenesis [211]. Here we report the utility of this platform in controlled delivery of HB-EGF 
for wound healing. 
3.2 MATERIALS AND METHODS – NORMAL WOUND HEALING 
3.2.1 HB-EGF coacervate preparation 
PEAD was synthesized as previously described [212, 213]. Heparin USP from porcine intestine 
(Scientific Protein Labs, Waunakee, WI) and PEAD were each dissolved at 10 mg ml-1 in sterile 
saline and 0.22 μm filter-sterilized. Heparin was initially combined with recombinant human 
HB-EGF (R&D Systems, Minneapolis, MN). PEAD was then added (50:10:1 mass ratio of 
PEAD:heparin:HB-EGF) which immediately precipitated the complex out of solution to form the 
HB-EGF coacervate, visible as a turbid solution.  
3.2.2 Fluorescent imaging of the coacervate 
A minimal amount of heparin (less than 1% by weight) in the coacervate was replaced with 
fluorescein (Aldrich Chemicals, Milwaukee, WI) by dissolving it in the heparin solution. The 
coacervate was centrifuged at 12,100 g for 10 min and the supernatant with unbound fluorescein 
was aspirated and replaced with deionized water. The coacervate was loaded to a glass chamber 
slide and imaged by an Olympus Fluoview FV100 confocal microscope (Olympus, Tokyo, 
Japan). 
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3.2.3 HB-EGF release profile 
200μl HB-EGF coacervate containing 1 μg HB-EGF was pelleted by centrifugation at 12,100 g 
for 10 min and placed at 37 ⁰C. On day 0, 1, 4, 7, and 10 the supernatant was aspirated and 
stored at -80 ⁰C, and 200μl fresh saline was replaced to cover the pellet. The amount of released 
HB-EGF in three separate fractions per timepoint was determined by ELISA (R&D Systems, 
Minneapolis, MN). 
3.2.4 In vitro scratch wound assay with primary human keratinocytes 
1x106 normal human epidermal keratinocytes (NHEK, Lonza, Basel, Switzerland) at passage 3 
were seeded per well in a 24-well plate and cultured in full keratinocyte growth media, KGM-
Gold (Lonza, Basel, Switzerland), until confluency. A 10 μl pipette tip was used to scratch the 
cell layer and wells were washed once with DPBS to remove debris. Cells were cultured at 37 ⁰C 
in KGM-Gold, without bovine pituitary extract (BPE) or epidermal growth factor (EGF) 
supplements, containing 100 ng ml-1 free HB-EGF or HB-EGF coacervate, or no HB-EGF as 
control. Photographs were taken of in vitro wounds in three wells per group with an Eclipse Ti 
inverted microscope (Nikon, Tokyo, Japan) at the beginning of the experiment and every 6 hours 
for one day. Scratch width was measured using NIS Elements Analysis software (Nikon, Tokyo, 
Japan). 
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3.2.5 In vitro proliferation of primary human keratinocytes 
2x105 passage 3 NHEK were seeded per well in a 24-well plate and cultured at 37 ⁰C in KGM-
Gold media, without BPE or EGF supplements, containing either 10 ng ml-1 or 1 ng ml-1 free 
HB-EGF or HB-EGF coacervate, or no HB-EGF as control. After 4 days cell lysates were 
prepared by the addition of 0.1 % Triton X-100 (Sigma, St. Louis, MO) followed by 3 freeze-
thaw cycles. Double-stranded DNA (dsDNA) content of cell lysates was measured by Quant-iT 
dsDNA high-sensitivity assay kit (Invitrogen, Carlsbad, CA).   
3.2.6 Murine wound model and wound closure analysis 
6-7 week old C57BL6/J mice (Jackson Labs, Bar Harbor, ME) were anesthesized with isoflurane 
and the dorsal area was shaved. Two 0.5 mm-thick silicone donut-shaped splints (OD=16 mm, 
ID=8 mm) were fixed on either side of the dorsal midline, approximately 2.5 cm from the ears, 
with 6-0 Prolene suture. Identical full-thickness wounds were made using a 5 mm round skin 
biopsy punch, centered within each splint. 1 μg free HB-EGF, as an HB-EGF coacervate, vehicle 
alone, or saline was applied to wounds (n=7 animals/ 14 wounds per group) by sterile pipet as a 
10 μl solution. Two wounds were made on each mouse to increase sample size and both wounds 
received the same treatment to avoid cross-contamination. Polyskin II sterile hydrocolloid 
bandages (Tyco Healthcare, Mansfield, MA) were applied followed by Coban self-adhesive 
wrap (3M, St. Paul, MN) around the midsection to deter chewing of the splints. On days 7, 10, 
14, and 17 only the wrap was removed and wounds were digitally photographed through the 
clear hydrocolloid bandage. Wound area was measured by blinded operator using a fine-
resolution computer mouse to trace the wound margin in MetaMorph Image Analysis Software 
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(Molecular Devices, Sunnyvale, CA). Suture and wraps were replaced as necessary to keep the 
splints fixed. On day 7, two animals per group were sacrificed and wounds and surrounding were 
tissue collected for histological evaluation. Remaining animals were sacrificed on day 17. 
University of Pittsburgh Institutional Animal Care and Use Committee (IACUC) approval was 
obtained prior to beginning all animal studies.  
3.2.7 Histological analysis 
Wound and surrounding tissue was collected using a 7 mm skin biopsy punch and then bisected 
through the midline of the wound using a razor blade. Both halves were immediately embedded 
in optimal cutting temperature (OCT) medium (Sakura Finetek, Torrance, CA), frozen, and 
sequentially sectioned at 5 μm using a MICROM HM525 cryomicrotome (Thermo Fisher 
Scientific, Waltham, MA). Only sections from the same area of the wound were compared 
histologically. Skin sections were stained with hematoxylin and eosin (H&E) for standard 
evaluation and with Masson’s trichrome staining (MTS) for evaluation of collagen content, 
counterstained with hematoxylin. 
3.2.8 Immunohistochemical analysis 
Wound sections were fixed and stained using a rabbit polyclonal anti-wide spectrum cytokeratin 
antibody (1:75, Abcam, Cambridge, MA) with an IHC staining kit (Santa Cruz Biotech, Santa 
Cruz, CA), then counterstained with hematoxylin. Day 7 sections were dual-stained using rabbit 
polyclonal anti-Ki-67 (1:500, Abcam, Cambridge, MA) and rabbit anti-integrin β4 (1:200, 
Abcam, Cambridge, MA) followed by goat anti-rabbit IgG Alexa Fluor 488 and Alexa Fluor 
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594-conjugated secondary antibodies (1:200, Invitrogen, Carlsbad, CA), respectively, and 
counterstained with DAPI. Day 17 skin sections were dual-stained with purified anti-mouse 
CD31 (1:50, BioLegend, San Diego, CA) followed by Alexa Fluor 588-conjugated secondary 
antibody (1:200, Invitrogen, Carlsbad, CA), and FITC-conjugated mouse anti-α-smooth muscle 
actin (α-SMA, 1:500, Sigma, St. Louis, MI).  All images were taken using an Eclipse Ti inverted 
microscope (Nikon, Tokyo, Japan). 
3.2.9 Statistical analysis 
Statistical analysis was performed using SPSS 16.0 software (SPSS Inc, Chicago, IL). Statistical 
differences were detected using analysis of variance (ANOVA) followed by Bonferroni 
correction as post-hoc testing. Differences were considered significant at P<0.05. 
3.3 RESULTS – NORMAL WOUND HEALING 
3.3.1 Characterization of HB-EGF coacervate 
PEAD contains two functional groups per repeating unit that carry positive charge (Fig. 11a). 
The coacervate forms immediately upon addition of PEAD to the heparin:HB-EGF complex in 
PBS, visible macroscopically as a turbid solution. Fluorescein carries negative charges and 
integrates into the coacervate via Coulombic forces. Fluorescent imaging of the coacervate with 
embedded fluorescein revealed spherical droplet with diameters ranging from 10-500 nm (Fig. 
11b).  The release kinetics of HB-EGF from the coacervate were determined in vitro. Less than 
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8% HB-EGF was detected in the supernatant after pelleting the coacervate (day 0 of release 
assay), indicating a loading efficiency of greater than 92%. No initial burst release of HB-EGF 
was observed on day 1, and release thereafter was approximately linear at 15 ng day-1 (Fig. 11c).  
 
 
 
Figure 11. The coacervate controls the release of HB-EGF in a steady fashion.   (a) Chemical structure 
of the PEAD. The backbone of PEAD contains aspartic acid and ethylene glycol diglyceride, connected by 
biodegradable ester bonds. Arginine is conjugated to provide two cationic charges per repeating unit, giving PEAD 
strong affinity for polyanions. (b) Confocal fluorescent imaging of fluorescein-labeled coacervate shows spherical 
morphology with droplet diameters of 10-500 nm. Bar = 1 μm. (c) In vitro release profile of HB-EGF from the 
coacervate into saline over 10 days. Bars indicate means ± SD. 
 
3.3.2 HB-EGF stimulates keratinocyte migration  
The effect of free and coacervate HB-EGF on the migratory capacity of primary human 
keratinocytes was determined by their ability to induce in vitro wound closure in a scratch assay. 
The closure of wounds made in confluent cell monolayers was tracked over 24 hours (Fig. 12a). 
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It is important to mention that cell proliferation may also affect closure rate in this assay, but the 
short timeframe limits its contribution. Though not statistically significant, the effect of bolus 
addition of free HB-EGF is evident 6 hours after wounding (Fig. 12b). By 12 hours post-
wounding, free HB-EGF significantly improved closure of scratch wounds compared to the 
control. Beginning 18 hours post-wounding, HB-EGF coacervate also significantly improved 
closure compared to the control. Scratch wound closure in free and coacervate HB-EGF groups 
was statistically the same at all timepoints. It is important to note that although the same amount 
of HB-EGF was added to both groups (100 ng ml-1), in the controlled delivery case it is mostly 
incorporated in the coacervate so the concentration of free growth factor in the medium is much 
lower. 
 
 
 
Figure 12. HB-EGF coacervate stimulates primary human keratinocytes.   (a) Representative images 
of scratch wounds on confluent keratinocyte monolayers after 24 h of culture in media supplemented with saline 
(Control), 100 ng ml-1 HB-EGF free or in the coacervate. Bars = 200 μm. (b) Quantification of percent closure of 
scratch wounds over time. Bars indicate means ± SD. *P<0.05; **P<0.01. (c) Quantification of cell number after 4d 
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culture of keratinocytes in media supplemented with saline (Control), 1 ng ml-1 or 10 ng ml-1 HB-EGF free or in the 
coacervate. Bars indicate means ± SD. **P<0.01. 
 
3.3.3 Controlled release of HB-EGF from the coacervate does not inhibit keratinocyte 
proliferation  
Primary human keratinocytes were cultured in the presence of free or coacervate HB-EGF in the 
culture media. Cell proliferation over 4 days culture was analyzed by DNA quantification. At 
high HB-EGF concentration (10 ng ml-1), free growth factor reduced cell proliferation compared 
to control while cell proliferation in the presence of coacervate with the same amount of growth 
factor had no statistically significant change (Fig. 12c). This is consistent with the premise of 
controlled release reducing the burst effect. At lower concentration (1 ng ml-1) however, neither 
free nor coacervate HB-EGF had any significant effect on cell number.  
3.3.4 HB-EGF coacervate accelerates mouse wound closure  
The effects of free and coacervate HB-EGF on wound closure were examined in a splinted 
mouse full-thickness excisional wound model. A modified skin biopsy punch wounding 
procedure led to a more uniform wound size than procedures requiring scissors. To mimic 
human healing, splints were used to avoid skin contraction, thus making re-epithelialization the 
major factor in wound healing. The wounds were treated immediately with saline, vehicle 
(PEAD:heparin complex), 1µg HB-EGF free or in the coacervate (Fig. 13a). Wound area was 
tracked over 17 days and animals were sacrificed on days 7 and 17 for histological analysis. 
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Accelerated closure of wounds treated with HB-EGF coacervate was evident by day 7 
and continued throughout the test period compared to all other groups (Fig. 13b-c). Only this 
treatment induced complete wound closure by day 17. No significant difference existed between 
the other three groups at any time point. Histological analysis after 7 days showed a thick cell-
rich granulation region in HB-EGF coacervate-treated wounds with high ECM content, revealed 
by Masson’s trichrome staining (MTS) (Fig. 14). Immunohistochemical detection of cytokeratin 
shows a thick stratum corneum on day 7 that was remodeled to identical structure to the 
surrounding normal epidermis by day 17 (Fig. 14). Signs of returning dermal appendages were 
also observed by day 17 in HB-EGF coacervate-treated wounds. Other groups showed thin and 
inconsistent granulation regions which stained less strongly with MTS. Positive cytokeratin 
staining was observed in all groups in dermal appendages such as hair follicles and sebaceous 
glands where epithelial cells also reside [214]. 
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Figure 13. HB-EGF coacervate accelerates healing of full-thickness wounds.   (a) Silicone donut-
shaped splints, fixed with suture, surrounded the wounds and forced healing to occur by re-epithelialization. 
Wounds were treated immediately with 10 μl of group-specific solution by sterile pipet. (b) Wound closure over 
time, measured as percent of original area. Fourteen wounds were averaged for day 7 timepoint after which two 
animals were sacrificed per group for histology; the remaining 10 wounds per group were photographed until 
sacrifice on day 17. Bars indicate means ± SD. *P<0.05; **P<0.01. (c) Representative photographs of wounds 
treated with saline, vehicle (PEAD:heparin complex), 1 μg HB-EGF free or in the coacervate. Ruler units are mm. 
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Figure 14. HB-EGF coacervate accelerates epithelialization and granulation.  Wound sections stained 
with hematoxylin and eosin (H&E) for general observation, Masson’s trichrome (MTS) for collagen, and 
immunohistochemically for cytokeratin (IHC-Cytokeratin) as a marker of epithelial cells. Representative light 
microscopy images of sections from the center of day 7 wounds are presented for all three staining methods, and of 
day 17 wound sections stained for IHC-Cytokeratin. Arrows indicate newly formed dermal appendages present 
within the granulation tissue. Bar = 500 μm.  
 
3.3.5 HB-EGF coacervate increases keratinocyte proliferative and migratory potential in 
vivo 
To further investigate the effect of HB-EGF on the behavior of keratinocytes after wounding, 
day 7 wound sections were immunostained for proliferation and migration. The former was 
reflected by Ki-67, a marker of cell proliferation [215]. The latter was observed by staining of β4 
integrins, which heterodimerize with α6 subunits on the surface of epithelial cells and play a key 
role in cell motility, especially during wound healing [216-218]. Both markers were localized 
almost exclusively to the epidermis (Fig. 15a). In the unwounded skin, normal epidermal 
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stratification was accurately reflected with β4 integrin -positive cells overlying cells positive for 
Ki-67; however the majority of cells at the wound margin were double-positive. Saline and 
vehicle groups showed minimal cell migration beyond the proliferating cells at the wound 
margin. Free HB-EGF induced migration of non-proliferating (Ki-67-negative) cells, consistent 
with the inhibited proliferation observed in vitro. In contrast, keratinocytes in wounds treated by 
HB-EGF coacervate exhibited co-localization of both markers well beyond the wound margin, 
indicating that the migratory cells still retain their proliferative capacity. Only HB-EGF 
coacervate-treated wounds showed a complete layer of epithelial (β4 integrin-positive) cells 
across the entire wound length on day 7.  
 
 
 
Figure 15. HB-EGF induces epithelial migration and proliferation.   (a) Immunofluorescent staining of 
day 7 wound sections for β4 integrin (red) and Ki-67 (green) with DAPI (blue) nuclear staining. High magnification 
images of the wound margin reveal epithelial cells with retained proliferation potential (co-localization of markers; 
red + green = yellow). Arrow indicates significant migration of these dual-positive cells. Bars = 200 μm. (b) 
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Immunofluorescent staining of day 17 wound sections for CD31 (red) and α-smooth muscle actin (green) with DAPI 
(blue) nuclear staining.  Representative images of granulation tissue near the wound margin show endothelial cell 
and mural cell infiltration from the adjacent dermis. Arrows indicate co-localization of cells (red + green = yellow) 
as potential nascent vessels. Bars = 50 μm. 
 
3.3.6 Angiogenesis accompanies faster healing 
The vascularization of day 17 wounds was examined with immunofluorescent staining for 
endothelial cells (CD31+) and mural cells (α-smooth muscle actin+). At the base of the 
granulation region near the wound margins, endothelial cells were observed in the HB-EGF 
coacervate-treated wounds (Fig. 15b). Additionally, mural cells were observed co-localizing 
with endothelial cells in the HB-EGF coacervate group, indicating early blood vessel formation 
not present in other groups. 
3.4 DISCUSSION – NORMAL WOUND HEALING 
Many delivery systems have been developed to provide controlled spatio-temporal release of 
EGF, including sponges [219], hydrogels [220], polymer pellets [221], electrospun nanofibers 
[91], and microspheres [222]. However, clinical translation of these systems has been deterred by 
setbacks such as poor loading efficiency, large initial burst release, and low bioactivity of the 
released growth factors [223]. It is likely that these challenges can be overcome by examining 
the integral role the ECM plays in sequestering, protecting, coordinating, and enhancing growth 
factor activity.  Thus, a particularly effective approach to design biomimetic growth factor 
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delivery systems is to incorporate ECM components such as hyaluronic acid [224], collagen 
[225], and vitronectin [226]. These systems utilize controlled release while also mimicking the 
natural extracellular environment of regenerating tissue [227]. 
Of similar structure to ECM-derived heparan sulfate proteoglycans, heparin is also used 
in many delivery systems [28]. In addition to protecting growth factors from proteolytic 
degradation, heparin potentiates the activity of some factors by facilitating their interaction with 
cell receptors [228, 229]. Delivering growth factors pre-bound to heparin also prevents their 
rapid sequestration by the endogenous ECM. This may be especially important in a cutaneous 
wound setting where growth factors are required at the wound margin to stimulate re-
epithelialization and are less useful if immobilized elsewhere in the wound [230]. In support of 
this notion is the finding that adding heparanase, which cleaves heparan sulfate thereby liberating 
bound growth factors, enhanced wound healing and angiogenesis [231].  
Our delivery approach is one of a handful of systems that utilize intact, native heparin, 
thereby fully retaining its natural functionality. Others have incorporated intact heparin by 
conjugation to fibrin matrices via bi-domain peptides [232], to peptide amphiphiles [233], or 
within dendrimer-crosslinked collagen gels [234]. Our delivery system employs a polycation that 
is a simplistic mimetic of the heparin-binding domain of the fibroblast growth factor receptor 
[235]. This bio-inspired ternary complex is stable, held together by polyvalent ionic interactions. 
Thus heparin imparts significant bioactivity to our delivery system, which PEAD keeps localized 
to the application site in a simple, unobtrusive way. This work represents, to the best of our 
knowledge, the first use of a bio-active controlled release system to deliver HB-EGF in a pre-
clinical animal model. 
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HB-EGF release from the coacervate, governed by degradation of PEAD and dissociation 
of the delivery complex, was slow and sustained over at least 10 days in vitro with a steady 
release rate of 15 ng per day. We expect that release is accelerated in vivo, driven by additional 
enzymatic activity in the wound bed. Degradation of the coacervate in vivo is catalyzed by 
esterases and heparinases, however we do not observe any toxic effects of PEAD or its 
degradation products, locally or systemically [212]. Indeed, the vehicle did not inhibit healing in 
the present study, showing no difference from the control. The viscous liquid-like properties of a 
coacervate, not too different from wound fluid, also make it highly attractive for use in a wound 
healing therapeutic. It is prepared in water and then simply applied topically in this work. The 
coacervate can also be injected [211] or could be incorporated into bandages. 
The effect of HB-EGF on epithelial cell proliferation and migration was examined 
individually using primary human keratinocytes. HB-EGF significantly increased keratinocyte 
migratory capacity but not proliferation, in accordance with previous reports [203]. HB-EGF 
coacervate consistently produced results similar to that of the free growth factor group; however, 
our release study shows that only 12% and 15% HB-EGF was released by the end of the 1 day 
migration study and 4 day proliferation study, respectively. This indicates an enhanced 
bioactivity of HB-EGF released from the coacervate. This is consistent with potentiated activity 
of fibroblast growth factors released from this delivery system [21]. Though not statistically 
significant, a slight advantage of free growth factor over coacervate was evident in the scratch 
migration assay, particularly during the first 12 hours. Interestingly, the difference in means 
between these two groups gradually decreased over the course of the experiment, reflecting the 
increasing concentration of HB-EGF in the medium in the coacervate group. At high 
concentrations, free HB-EGF inhibited cell proliferation, as previously reported [202]. However, 
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using the coacervate to maintain a low, stable concentration of free HB-EGF avoided this 
inhibition. 
Splinted excisional wound models in rodents force healing to occur by re-
epithelialization as in humans, rather than by contraction as in most loose-skinned mammals 
[236].  Thus they provide an ideal first validation tool for the potential of HB-EGF coacervate to 
accelerate wound closure in vivo. We found that controlled delivery is essential to effective HB-
EGF therapy, as free growth factor healed wounds at the same rate as controls at a dosage of 1 
μg. HB-EGF coacervate significantly accelerated wound closure over 17 days by comprehensive 
healing which included expedited re-epithelialization, improved granulation tissue formation, 
and angiogenesis.  
Endogenous HB-EGF expression is normally low but is upregulated in cutaneous wounds 
[202]. It is produced by multiple cells and in the setting of dermal injury acts primarily as a 
potent stimulator of re-epithelialization [203]. The presence of exogenous HB-EGF delivered by 
the coacervate accelerated re-epithelialization, as evident by a complete keratinized layer with 
regained barrier function 7 days after administration. We also observed keratinocytes well 
beyond the wound margin which stained positive for β4 integrin co-localized with Ki-67 protein, 
expressed exclusively in nuclei of cells in active cell cycle. In agreement with our in vitro results, 
these migrating keratinocytes continued to proliferate as long as the soluble HB-EGF 
concentration was maintained below threshold levels by the coacervate. Conversely, free HB-
EGF stimulated cell migration beyond that of the controls, however proliferation was restricted 
to near the wound margin and ultimately led to no difference in wound closure rate. 
In the first week of acute wound healing, dermal fibroblasts enter the wound bed, 
proliferate, and gradually replace the provisional fibrin- and fibronectin-rich matrix with a 
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collagenous one, also containing proteoglycans. This collagen matrix, primarily type I and III, 
serves as inductive scaffolding for infiltrating stromal cells and provides strength and structure to 
the new tissue as remodeling occurs [237, 238]. HB-EGF may act as a fibroblast mitogen and 
indeed, we observed that granulation tissue in HB-EGF coacervate-treated wounds had high 
collagen content 7 days after injury. This likely resulted from both direct effects on dermal 
fibroblasts and indirect effects such as activation of paracrine signaling by epithelial cells [239]. 
The presence of dermal appendages within the granulation region at day 17 further indicates that 
HB-EGF coacervate-treated wounds were at a later stage of healing compared to other groups.   
Angiogenesis also plays a critical role in the wound healing process. Endothelial sprouts 
derived from adjacent tissue invade the provisional wound matrix and support the formation of 
granulation tissue [238]. HB-EGF may have direct mitogenic and motogenic effects on 
endothelial cells [206] and vascular smooth muscle cells [205], or may influence the angiogenic 
process by initiating paracrine signaling by keratinocytes and fibroblasts in the wound bed. HB-
EGF may also be involved through the stimulation of matrix metalloproteinases (MMPs), which 
are critical in the initial stages of angiogenesis [240]. Our results indicate that controlled release 
of HB-EGF to the wound seemed to induce endothelial cell infiltration and signs of nascent 
blood vessels, not observed in other groups. The exact mechanisms by which HB-EGF affects 
angiogenic response require further investigation. 
3.5 INTRODUCTION – DIABETIC WOUND HEALING 
The global prevalence of diabetes mellitus was 382 million in 2013 and is projected to rise to 
592 million by 2035 [241]. Fifteen percent of diabetics will develop a skin ulcer in their lifetime 
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resulting from neuropathies, peripheral ischemia, and infection [242]. Healing of diabetic ulcers 
does not progress normally but rather is plagued by an abnormal inflammatory response, low 
growth factor availability, and impaired cell function and angiogenesis, among others 
deficiencies [22]. Unsuccessful treatment of diabetic ulcers drives exorbitant healthcare costs, 
leads to substantial pain and morbidity, and precedes 85% of all non-traumatic foot amputations 
[243]. Clearly, therapies to initiate and accelerate the healing of diabetic wounds are important 
and timely. 
Growth factors (GF) orchestrate the process of tissue repair in the body and thus hold 
great potential for regenerative therapies if applied strategically. However, their clinical use is 
currently limited by the fact that if applied alone, they are rapidly degraded and removed from 
the site of application [244]. Chronic wounds have particularly high protease activity and are 
deficient in extracellular matrix heparan sulfate proteoglycans which play a critical role in GF 
signaling [9, 245]. As a result, most experimental GF therapies have required frequent 
applications and high dosages to have positive albeit marginal effects on healing outcomes [4, 
244]. We hypothesized that a delivery system releasing the GF pre-stabilized by heparin sulfate 
could circumvent the deficiencies of chronic wounds and promote their healing.  
Unlike many GF evaluated for wound healing, HB-EGF is a pleiotropic factor 
influencing many stages of the wound healing process such as re-epithelialization, granulation 
tissue deposition and remodeling, wound contraction, and angiogenesis [161, 203, 206, 246]. 
HB-EGF is also a matrikine factor which requires the presence of heparin for binding and 
activation of its cell receptors [247, 248]. Thus we developed a heparin-based coacervate 
delivery system to provide sustained, localized release of HB-EGF in a chronic wound 
environment. We designed a simple polycation, poly(ethylene argininylaspartate diglyceride) 
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(PEAD), that self-assembles with heparin to form a complex coacervate, a liquid-liquid 
separation held together by electrostatic interactions between oppositely charged molecules. HB-
EGF is bound to heparin and thus encapsulated by the liquid coacervate droplets and separated 
from the aqueous environment. The coacervate may then be applied directly to the wound and 
covered with an occlusive dressing where it will slowly and steadily release HB-EGF [141]. This 
delivery system is ideal for HB-EGF as it offers both protection from proteolytic degradation, 
and potentiation of GF bioactivity by mimicking the signaling environment in normal wounds 
where healing proceeds unhindered. The aim of this study is to evaluate the potential of HB-EGF 
coacervate as a therapy for diabetic wound healing using a genetically type 2 diabetic mouse 
model. We expect the impact of this heparin-based coacervate to extend beyond treatment for 
diabetic wounds. We believe it is a platform technology for delivery of any heparin-binding 
factor and combinations thereof for many applications.  
3.6 MATERIALS AND METHODS – DIABETIC WOUND HEALING 
3.6.1 HB-EGF coacervate preparation 
PEAD was synthesized as we have described previously [249]. PEAD and heparin USP 
(Scientific Protein Labs, Waunakee, WI) were each dissolved in 0.9 % saline at 10 mg/ml and 
filtered at 0.22 μm to sterilize. Heparin was initially combined with recombinant human HB-
EGF (R&D Systems, Minneapolis, MN) and PEAD was then added. Immediately following 
addition of the polycation the HB-EGF coacervate self-assembled and was visible as a turbid 
solution. 
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3.6.2 Diabetic mouse wound healing model 
Approval was received by the University of Pittsburgh’s Institutional Animal Care and Use 
Committee (IACUC) prior to beginning all animal work. Male 10-week old NONcNZO10/LtJ 
mice (Jackson Labs) were fed a minimum 10 % fat diet to maintain their diabetic phenotype. 
Blood glucose was assessed prior to wounding and at the time of sacrifice using an AlphaTRAK 
veterinary glucometer (Abbott). A blood glucose level of 200 mg/dL was considered diabetic and 
animals with lower levels were excluded from the study. Mice were anesthetized with isoflurane 
and dorsal hair was removed with depilatory cream (Nair). Two identical 5 mm full-thickness 
wounds including the panniculous carnosus were created using a round skin biopsy punch. 
Saline, 1 µg Free HB-EGF, or 1 µg HB-EGF coacervate was applied to the wound by sterile 
pipet as a 10 µl solution. Both wounds on each mouse received the same treatment to avoid 
cross-contamination. A Polyskin II hydrocolloid dressing (Tyco Healthcare) was applied 
followed by Coban self-adhesive wrap (3M) around the midsection. Animals were sacrificed on 
days 3, 7, 14, and 28 and wounds and surrounding tissue were collected for histological analysis.  
3.6.3 Histological analysis 
Skin tissue was immersed in Tissue-Tek O.C.T. Compound (Sakura), frozen, and 5 µm 
sequential sections were cut using a MICROM HM525 cryomicrotome (Thermo Fisher 
Scientific). Only sections from the center of the wound were used for analysis.  Slides were fixed 
in 2% paraformaldehyde and blocked in 5% normal goat serum (Sigma) for 1 h at 37 ˚C. Primary 
antibodies used included rabbit anti-wide spectrum cytokeratin (1:200, Abcam), rabbit anti-Ki-67 
(1:400, Abcam), rabbit anti-vWF (1:400, Abcam) and anti-α-SMA (1:500, Sigma). Primary 
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antibodies were incubated for either 1 h at 37 ˚C or overnight at 4 ˚C. Goat anti-rabbit IgG Alexa 
Fluor 488 and Alexa Fluor 594-conjugated secondary antibodies (1:200, Invitrogen) were 
incubated for 45 m at 37 ˚C. All slides were counterstained with DAPI (Sigma). Slides were also 
stained with hematoxylin and eosin (Ricca) or with Picosirius Red Stain Kit (Polysciences Inc.) 
following the manufacturer’s protocols. All images were acquired using an Eclipse Ti inverted 
microscope (Nikon) and all image analyses were performed using NIS Elements Version 3.2 
software (Nikon).  
3.6.4 Wound healing assessments 
Re-epithelialization was measured in day 3 and day 7 wound sections stained for pan-
cytokeratin. The total wound length (WL), left neo-epithelial length (LL), and right neo-
epithelial length (RL) were measured using the innermost hair follicles on each side to delineate 
the wound margins. Percent re-epithelialization was calculated as: Re-epithelialization (%) = 
[(LL+RL)/WL] *100 %. Proliferating keratinocytes were identified in day 3 wound sections 
stained for pan-cytokeratin and Ki-67 as cells co-expressing these markers in the basal layer of 
the neo-epidermis. The number of these cells beyond the wound margin was counted and 
normalized to the total number of DAPI nuclei counted in the basal epidermis. Collagen content 
was measured in day 14 and day 28 wound sections stained with Picosirius Red. Wounds were 
observed under polarized light which illuminates collagenous structures bright red. The wound 
zone perimeter was traced as the region of interest and area fraction positive for collagen was 
quantified using image thresholding. Wound contraction was evaluated in day 14 and day 28 
sections stained with hematoxylin and eosin. The gap between wound margins, indicated by the 
innermost hair follicles on each side of the wound, was measured and reported as the contraction 
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gap. Blood vessels were observed in day 28 wound sections stained for vWF and α-SMA. The 
number of endothelial tubes was counted as vWF-positive cross-sectional or longitudinal tubes in 
the neo-dermal region. Mature vessels were counted as those endothelial tubes which also had 
adjacent α-SMA-positive cells. Both measurements were normalized to the total wound area 
(mm2) for each wound.  
3.6.5 Keratinocyte scratch migration assay 
Diabetic and normal human epidermal keratinocytes (Lonza) were cultured in Keratinocyte 
Growth Medium-Gold (Lonza) and used at between passages 3-4. Cells were seeded at 2x106 per 
well in a 24-well plate and cultured to confluency. A single scratch was made through the center 
of each well using a 1 ml pipette tip and wells were then rinsed once with DPBS to remove cell 
debris and 0.5 ml media was added. HB-EGF dosages of 10, 100, or 250 ng/ml were added to the 
media in free-form or incorporated within the coacervate, formed at a 500:100:1 mass ratio of 
PEAD:heparin:HB-EGF. One group of DHEK and the NHEK received no HB-EGF as controls. 
Scratch width was measured in the center of 3 wells per group at 0, 6, 12, and 18 hours and 
reported as percent scratch closure.  
3.6.6 Statistical analysis 
Statistical analysis was performed using Minitab 16.0 software (Minitab Inc., State College, PA). 
Data was tested for normality and equal variance before analysis. Statistical differences were 
calculated using analysis of variance (ANOVA) followed by Tukey post-hoc testing. Differences 
were considered significant at p < 0.05. 
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3.7 RESULTS – DIABETIC WOUND HEALING 
3.7.1 HB-EGF coacervate accelerates re-epithelialization of diabetic wounds  
To evaluate the effects of HB-EGF in diabetic wounds, we used the NONcNZO10/LtJ strain of 
genetically type 2 diabetic mice available from Jackson Labs. Although porcine skin is most 
similar to that of humans, there is no established porcine model that captures the pathology of 
type 2 diabetes. Of the rodent models currently available, the NONcNZO10/LtJ best resembles 
the presentation of type 2 diabetes in humans [250-252]. We created 5 mm full-thickness 
excisional dorsal wounds, then applied a single dose of HB-EGF coacervate (containing 1 µg 
HB-EGF), the same amount of HB-EGF in free-form, or saline only, and we tracked their 
healing over 4 weeks. We first assessed the rate of re-epithelialization, characterized by 
epithelial cell migration into the wound to form a new protective epidermis. We identified 
epidermal cells in the wounds by immunofluorescence staining for cytokeratin and reported their 
lengths of migration as a percent of the total wound length (Fig. 16a). Three days after 
wounding, we observed that HB-EGF coacervate had significantly increased re-epithelialization 
compared to the other groups (Fig. 16b). Furthermore, the same 1 µg dose of HB-EGF applied in 
free-form without the protection of the coacervate showed no significant difference from the 
saline group. This trend continued to day 7, at which point re-epithelialization in the HB-EGF 
coacervate group was more than 85 % complete whereas in saline and free HB-EGF groups it 
was less than 55 %. These data indicate that HB-EGF coacervate can induce diabetic mouse 
epidermal cell migration and we next evaluated its effect on their proliferative capacity.  
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Figure 16. Wound re-epithelialization on day 3 and day 7.   (A) Wound sections were stained for pan-
cytokeratin (red) and counterstained with DAPI (blue). Re-epithelialization was measured as the percentage of the 
total wound length (WL) covered by both the right (RL) and left neo-epithelial lengths (LL). Bar = 100 μm. (B) 
Percent re-epithelialization measured on day 3 and day 7. Data represent means ± SD of 6-8 wounds per group per 
timepoint, *p < 0.05, **p <0.01. 
 
3.7.2 HB-EGF coacervate stimulates diabetic keratinocyte proliferation 
In the classical paradigm of wound repair, keratinocyte proliferation occurs in order to contribute 
to the re-epithelialization process, however it is limited to the cells located at the wound margin 
[253]. We wondered if stimulation by HB-EGF throughout the wound bed might encourage 
epidermal cells to maintain their proliferative capacity even as they migrated into the wound. We 
identified proliferating keratinocytes in the basal layer of the neo-epidermis by 
immunofluorescence staining for Ki-67, which is exclusively expressed in the nucleus of cells in 
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active cell cycle [254]. As expected, in the saline and free HB-EGF treated wounds, Ki-67+ 
keratinocytes were mostly located at the wound margin on day 3 (Fig. 17a,b), and only 24% and 
28% of keratinocytes beyond the wound margin were proliferative, respectively (Fig. 17d). On 
the other hand, 61% of keratinocytes beyond the wound margin were positive for Ki-67 in HB-
EGF coacervate treated wounds and these cells were distributed throughout the basal neo-
epidermis, even out to the tip of the leading edge (Fig. 17c). These results demonstrate that HB-
EGF can increase keratinocyte proliferation during diabetic wound repair, provided sufficient 
concentrations of active GF exist in the wound bed. They also indicate that cell proliferation 
likely contributed to the faster re-epithelialization observed in HB-EGF coacervate wounds, 
although the relative contributions of migration and proliferation to this end require further 
investigation. 
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Figure 17. Basal keratinocyte proliferation on day 3.  Wounds treated with (A), Saline (B) Free HB-
EGF, or (C) HB-EGF coacervate, were stained for pan-cytokeratin (red), Ki-67 cell proliferation marker (green), and 
DAPI (blue), thus the nuclei of proliferating keratinocytes appear yellow. Indicated regions of the left column are 
magnified in the center and right columns. Dotted lines indicate the wound margin. Arrows indicate Ki-67+ 
keratinocytes in the basal neo-epidermis. Bars = 100 μm. (D) Ki-67+ cells beyond the wound margin were counted 
and reported as a percent of the total number of DAPI nuclei in the basal epidermis. Data represent means ± SD of 
6-8 wounds per group, **p <0.01. 
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3.7.3 HB-EGF coacervate increases collagen deposition in diabetic wounds 
To further test the benefit of HB-EGF coacervate in diabetic wound healing, we examined the 
wound granulation and remodeling processes after 2 and 4 weeks. We evaluated the quantity and 
arrangement of collagen fibers in Picosirius Red stained wound sections by polarized light 
microscopy. The stain accentuates the birefringent properties of collagen and allows observation 
as bright red fibers against a black background, permitting quantification of the collagen-positive 
area (Fig. 18a). Within the granulation region on day 14, there was a slightly greater collagen-
positive area in HB-EGF coacervate wounds compared to others, yet this result was not 
statistically significant (Fig. 18b). However, by day 28 collagen content in wounds treated with 
HB-EGF coacervate was more than twice that of the other groups and closest to that of the 
normal NONcNZO10 mouse dermis (35.6 ± 8.7 %) with most fibers in parallel orientation, 
although the fibers are shorter and thinner. These data indicate that over 4 weeks, HB-EGF plays 
a role in the activities of dermal fibroblasts in the wound bed including provisional matrix 
remodeling and collagen deposition.   
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Figure 18. Collagen content of wounds on day 14 and day 28.   (A) Representative images of day 28 
wounds and normal skin stained with Picosirius Red and evaluated under polarized light to observe collagen. Bars = 
100 μm. (B) The percent of the wound region positive for collagen was quantified. Data represent means ± SD of 6-
8 wounds per group per timepoint, **p <0.01. 
 
3.7.4 HB-EGF coacervate enhances diabetic wound contraction 
The functional readout of a healthy, collagenous wound matrix is wound contraction. During this 
process myofibroblasts anchor to the collagen fibers and begin to pull the wound margins 
together. We evaluated wound contraction at week 2 and week 4 by measuring the gap between 
the wound margins, identified by the innermost hair follicle on each side of the wound (Fig. 19a-
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c). On day 14, wounds treated with HB-EGF coacervate had a significantly smaller contraction 
gap compared to saline treated wounds (Fig. 19d). Although free HB-EGF appeared to have a 
small beneficial effect on contraction at 2 weeks, it was not significantly different from either 
group. On day 28, contraction in HB-EGF coacervate treated wounds was nearly complete and 
the contraction gap was significantly smaller than in both the saline and free HB-EGF groups. 
Clearly, the robust collagen matrix in HB-EGF coacervate wounds preceded an improved 
contraction response and faster wound closure.  
 
 
Figure 19. Wound contraction on day 14 and day 28.  Wounds treated with (A) Saline, (B) Free HB-
EGF, or (C) HB-EGF coacervate were stained with hematoxylin and eosin. Arrows indicate boundaries of the 
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contraction gap. Bars = 500 µm. (D) Wound contraction was quantified by measuring the gap between the wound 
margins. Data represent means ± SD of 6-8 wounds per group per timepoint, *p <0.05. 
 
3.7.5 HB-EGF coacervate encourages diabetic wound re-vascularization 
Another sign of neo-dermal maturity is the formation of blood vessels to support the new tissue. 
We used immunofluorescence staining to evaluate the vessel numbers present in the granulation 
region on day 28, staining for von Willebrand Factor (vWF) as an endothelial cell marker and 
alpha smooth muscle actin (α-SMA) to identify mural cells (pericytes or smooth muscle cells) 
(Fig. 20a). We found significantly more endothelial tubes within the neo-dermis of HB-EGF 
coacervate treated wounds compared to others (Fig. 20b), and also more mature vessels, 
classified as those endothelial tubes which had mural cell stabilization (Fig. 20c). These data 
demonstrate that sustained delivery of HB-EGF can promote angiogenesis in a diabetic wound 
environment. We conclude that HB-EGF coacervate treatment leads to an advanced state of 
healing compared to saline and free HB-EGF treatment by 4 weeks after wounding.   
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Figure 20. Wound re-vascularization on day 28.   (A) Wounds and normal skin were stained for vWF 
(red) to indicate endothelial cells and α-SMA (green) for mural cells. Bars = 100 μm. (B) Endothelial cell (EC) tubes 
were identified as vWF+ vessel structures and quantified. (C) Mature vessels were identified as endothelial tubes 
stabilized by mural cells and quantified. Data represent means ± SD of 6-8 wounds per group, *p <0.05, **p <0.01. 
 
3.7.6 HB-EGF coacervate stimulates migration of diabetic human cells in vitro 
As a test of clinical relevance, we assessed the effect of HB-EGF coacervate on diabetic human 
epidermal keratinocytes (DHEK) in a scratch wound migration assay. We scratched confluent 
monolayers of the cells to mimic epithelial injury and then measured the percent scratch closure 
by cell migration. With no HB-EGF added, DHEK displayed impaired migration by 18 h post-
 83 
wounding compared to normal human epidermal keratinocytes (NHEK) (Fig. 21a). However, 10 
ng/ml of HB-EGF, both free and in the coacervate, significantly increased DHEK migration by 6 
h, and the scratches were completely healed by 12 h (Fig. 21b). Overexpression of HB-EGF has 
been previously shown to exert an inhibitory effect on epithelial cells [162]. Consistent with 
those findings, we observed no significant benefit of free HB-EGF at concentrations of 100 
ng/ml at 6 h and 250 ng/ml at 12 and 18 h (Fig. 21c,d). On the other hand, those same 
concentrations of HB-EGF delivered by the coacervate did significantly stimulate cell migration 
compared to the DHEK control group and the corresponding free HB-EGF group. These data 
demonstrate that HB-EGF coacervate can stimulate diabetic human cells and can circumvent the 
limitations of free GF administration.  
 
 
Figure 21. In vitro scratch wound migration assay with human keratinocytes.   (A) NHEK or DHEK 
cultured with no HB-EGF as controls. (B) DHEK cultured with 10 ng/ml HB-EGF free or in the coacervate (C) 
DHEK cultured with 100 ng/ml HB-EGF free or in the coacervate (D) DHEK cultured with 250 ng/ml HB-EGF free 
or in the coacervate. Data represent means ± SD of 3 samples per group per timepoint, *p < 0.05 compared to 
 84 
DHEK control group at similar timepoint, #p < 0.05 compared to free HB-EGF group at similar timepoint and 
dosage. 
3.8 DISCUSSION – DIABETIC WOUND HEALING 
Conventional treatment of diabetic ulcers includes debridement, off-loading pressure, and 
maintenance of a moist wound environment with frequent dressing changes [242]. If wounds do 
not show signs of healing with standard treatment, advanced biological therapies are employed 
such as Regranex, the only recombinant GF therapy currently approved by the FDA for skin 
wound healing [255]. Regranex contains  recombinant human platelet-derived growth factor 
suspended in a carboxymethyl cellulose gel which offers minimal protection of the GF, leaving it 
prone to rapid degradation in the protease-rich wound environment [245]. Frequent applications 
and high doses are therefore necessary to produce a positive, albeit marginal effect on healing 
outcomes [256]. However, high doses also pose a risk of inducing tumor formation [69] and can 
also be cost-prohibitive in low- and middle-income countries where diabetes is also prevalent 
[241]. Unfortunately, these shortcomings have significantly limited its clinical use [257, 258]. 
Dosage reduction is therefore a key aim of our approach. In this study, we used a GF dosage per 
wound area that is approximately 1000-fold lower than Regranex. Furthermore, the coacervate is 
phase-separated from wound fluid which keeps the GF localized to site of application by 
preventing systemic uptake. Altogether, we do not anticipate undesirable side effects of this 
therapy in humans. 
The half-life of HB-EGF after intravenous and gastric administration is 26 m and 11 h, 
respectively [259] and is likely to be even shorter in a wound environment which has high 
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proteolytic activity [245]. Consequently, numerous delivery systems have been developed for 
protection and sustained release of epidermal growth factor (EGF) family proteins and tested in 
animal models of diabetic wounds [4]. One focus has been employment of sulfated 
proteoglycans such as heparan sulfate, which play a key role in the human body of providing 
stabilization, localization, and potentiated bioactivity of signaling molecules [9, 260]. These 
benefits have motivated the incorporation of heparin or heparin-mimetic components into many 
different types of delivery systems for proteins [261]. However, few systems use heparin in its 
native form, unconjugated to any scaffold or gel. Covalent conjugation may affect its properties 
such as its charge density and macromolecular structure which could reduce its binding affinity 
to certain proteins which rely on specific oligosaccharide sequences [262-264]. Several benefits 
of heparin in its native form have been elucidated by complexing it with peptide amphiphiles for 
protein delivery [15, 265]. Intact heparin is particularly appealing for delivery of HB-EGF as it is 
required for binding and phosphorylation of EGF cell receptors [247, 248]. This motivated our 
development of a simple delivery system utilizing intact heparin to load HB-EGF and facilitate 
its biological activities. 
PEAD is a synthetic polycation designed to mimic the strongly cationic domain of the 
fibroblast growth factor receptor which interacts with heparin through polyvalent charge 
attraction [11, 12]. By similar mechanism, PEAD:heparin:GF complexes self-assemble and form 
micron-sized coacervate droplets which are phase-separated from water and thereby protect the 
incorporated GF from proteolysis [249]. Preservation of heparin in its native conformation 
enables its interaction with cell receptors and potentiates GF bioactivity [20, 21, 136, 160, 166, 
169]. The coacervate incorporates 1 µg HB-EGF with greater than 92% loading efficiency and 
then releases approximately 15 ng per day with no initial burst release [141]. PEAD was 
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designed with a hydrolytically cleavable backbone, resulting in slow biodegradation which 
releases HB-EGF and heparin. Release may also occur in part by disassembly of the coacervate 
due to ionic interference. PEAD has been demonstrated to be non-cytotoxic; it does not elicit an 
appreciable inflammatory response or any adverse effects when injected subcutaneously in rats 
[249]. We have also demonstrated that the unloaded coacervate has no significant effect on the 
healing process of excisional wounds in mice [141]. For these reasons we elected not to include 
the coacervate alone as a control group in this study. 
NONcNZO10 mice were selected for this study from numerous diabetic mouse models 
available. Unlike chemical induction with streptozotocin or the db/db monogenic strain, 
NONcNZO10 mice display moderate obesity, whole-body insulin resistance, and an age-
associated progression of metabolic abnormalities resembling those of the human diabetic 
condition [252]. The shortcomings of monogenic models in replicating a polygenic disease like 
diabetes mellitus are underscored in studies showing that wound closure rates of db/db mice do 
not correlate with the severity of their diabetic condition [250, 266]. On the other hand, models 
with polygenic etiology provide a better representation of the genetic and metabolic profiles of 
diabetes in humans. In a recent comparison of four common diabetic mouse strains, only 
NONcNZO10 mice exhibited impairment in every step of the wound healing cascade [250]. It is 
worth noting that a second polygenic strain, TallyHo/JnJ, displays similar phenotype to 
NONcNZO10 and will also prove useful for studies of diabetic wound healing in the future 
[251].  
We previously reported that coacervate delivery of HB-EGF accelerates scratch wound 
closure of NHEK and avoids the inhibitory effect of HB-EGF on keratinocyte proliferation in 
vitro [141]. We also demonstrated in vivo that HB-EGF coacervate accelerates re-
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epithelialization and stimulates keratinocyte proliferation in full-thickness wounds on C57BL/6 
mice [141]. We performed similar evaluations in diabetic wounds as reduced cell proliferation is 
one key complication leading to non-healing chronic ulcers [22]. We observed more than twice 
the number of Ki-67+ cells in HB-EGF coacervate treated diabetic wounds compared to saline 
treatment. Moreover, these cells were distributed out to the tips of epithelial leading edges, 
whereas proliferative cells in saline wounds were mainly limited to the margins as is typical 
[203]. These results indicate that, additional to enhanced migration, keratinocyte proliferation 
also contributed to wound re-epithelialization. We conclude that stimulation of diabetic 
keratinocytes by HB-EGF coacervate is sufficient for them to overcome several phenotypical 
impairments of their diabetic condition. 
HB-EGF plays an important role in the process of remodeling the largely fibrin-based 
provisional matrix to a robust collagenous matrix [246]. The quantity and quality of collagen 
deposited is critical to other processes such as wound contraction and re-vascularization. 
Unfortunately, matrix remodeling is often severely impaired in chronic wounds [24, 267].  
Nonetheless, we found the collagen content of HB-EGF coacervate treated wounds to be 
significantly higher than that of other groups after 4 weeks of healing. Consequently, wound 
contraction was also accelerated because myofibroblasts were able to securely attach to the 
collagen matrix and begin to pull the wound margins together. Taken together, these data 
demonstrate that sustained release of HB-EGF in a diabetic wound environment can stimulate 
dermal fibroblasts to improve the overall wound maturation process and contribute to timely 
closure. 
Angiogenesis is a critical process in the wound healing cascade which provides oxygen, 
nutrients, and cells the wound bed and contributes to waste removal [268]. HB-EGF has been 
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previously demonstrated to promote angiogenesis through some direct and some indirect 
pathways acting on endothelial cells and vascular smooth muscle cells [205, 206, 269, 270]. Our 
results indicate that HB-EGF coacervate increases the numbers of both neo-vessels and stable, 
mature vessels in diabetic wounds after 4 weeks of healing. 
We and others have reported that the migratory capacity of NHEK is enhanced by HB-
EGF [141, 203]. Here, we demonstrate that HB-EGF has a similar effect on diabetic cells. Low 
concentration (10 ng/ml) of HB-EGF, both free and in the coacervate, significantly stimulated 
DHEK migration compared to control groups. However, higher concentrations of free HB-EGF 
did not have this effect. The benefit of controlled release is apparent when the same 
concentrations of HB-EGF in the coacervate did successfully stimulate DHEK. These results 
indicate that the coacervate alters the concentration of HB-EGF available to cell receptors, 
avoiding the inhibitory effect of high dosages which oversaturates receptors [141, 162]. 
Furthermore, we proved that diabetic human cells respond well to HB-EGF released from the 
coacervate, which clears a major translational hurdle towards making this experimental therapy a 
clinical reality.  
3.9 CONCLUSIONS 
This study assesses the benefit of a controlled release approach to the utility of HB-EGF therapy 
for wound healing. We demonstrated that sustained coacervate-based delivery of HB-EGF 
significantly accelerated wound closure within 17 days, while free growth factor application had 
no effect on closure rate compared to controls. Keratinocyte migratory capacity was significantly 
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increased and proliferative capacity was maintained by HB-EGF coacervate. This led to 
accelerated wound re-epithelialization which was accompanied by healthy granulation tissue 
formation and angiogenesis. These results suggest that coacervate-based controlled delivery of 
HB-EGF can induce fast and comprehensive healing of cutaneous wounds. 
In summary, we elucidated the multifunctional role of HB-EGF in the chronic wound 
healing process, provided sufficient levels exist in the wound bed. HB-EGF released from the 
coacervate stimulated human keratinocyte migration in vitro, and in a diabetic wound model 
enhanced re-epithelialization, wound matrix remodeling, and wound contraction and re-
vascularization. HB-EGF coacervate represents a promising regenerative therapy for diabetic 
wounds. In the future, the efficacy of this HB-EGF coacervate will be evaluated using diabetic 
pigs, which are the standard pre-clinical model for therapies to treat diabetic wounds.  
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4.0  CONTROLLED DELIVERY OF SONIC HEDGEHOG TO PROMOTE CARDIAC 
REPAIR 
4.1 INTRODUCTION 
Ischemic heart disease is now the leading cause of death in the U.S. and worldwide [271]. 
Myocardial infarction (MI) is the most prevalent life-threatening manifestation of progressed 
heart disease and those who survive often develop congestive heart failure [170]. Heart failure 
afflicts 5.7 million Americans, a prevalence that is expected to rise 25% by 2030 [272]. The 
treatments patients currently receive after MI aim to slow the progression of heart failure [273], 
with total heart transplantation being the gold standard; still there is insufficient donor 
availability and is not without complications [274]. Thus new therapies seeking to preserve and 
regenerate the patient’s own heart following MI are urgently needed.  
Numerous candidate technologies have been developed for alleviating or reversing the 
damage caused by cardiac ischemia [275-277]. These technologies fall into two general 
categories: bioactive therapies or structural “bulking” therapies. The former aims to provide the 
necessary resources for tissue regeneration, and several therapeutic approaches including stem 
cells [278-281], growth factors [282], and gene therapy [283] have been evaluated in U.S. 
controlled clinical trials. On the other hand, the primary aim of structural therapies is to reinforce 
the damaged heart wall and thereby alleviate wall stress and prevent wall thinning and 
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ventricular dilation [276, 277]. Clinical trials have been initiated to evaluate intramyocardial 
injections of alginate and cell-seeded collagen [284]. However, no regenerative therapy, 
biological or structural, has shown enough promise to receive FDA approval.  
The best therapy may involve “master switch” agents which activate multiple 
downstream pathways [285]. Sonic hedgehog (Shh) is one such master regulator, acting as a 
powerful morphogen during development when it typically influences cell fate but can also 
affect cell growth and survival [286, 287]. Shh signaling remains active in the adult mammalian 
heart at very low levels though it is upregulated during ischemic heart injury such as myocardial 
infarction (MI) and congestive heart failure [163, 288]. Currently, damage to the adult heart is 
considered permanent as cardiomyocytes have limited proliferative capability and fibrosis occurs 
post-MI instead of healing [273, 289]. However, during development, when cardiac tissue 
patterning is controlled by powerful morphogens such as Shh [290], the embryonic mammalian 
heart briefly displays the ability to regenerate itself [291]. Temporarily recapitulating this 
embryonic signaling environment through exogenous application of cardiac morphogen Shh is 
therefore a possible approach towards repair of the damaged adult heart. 
Shh has previously been applied to the heart as a free protein. Direct injection has been 
shown to restore blood flow in a critical hindlimb ischemia model [164]. However, this approach 
is highly inefficient due to short morphogen half-lives in the body [292] and therefore requires 
multiple injections. High dosage is also necessary to elicit a desired effect which is expensive 
and may carry similar safety concerns to gene therapy. Investigations using gene therapy [163, 
293] and transduced cell therapy [165] have been shown to improve cardiac function following 
MI. However, both of these approaches carry high risk of inducing tumor formation, especially 
considering the potency of morphogens [294], and thus trials have not progressed beyond large 
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animal models. On the contrary, a controlled delivery approach provides stabilization and 
protection of Shh and can release it slowly to maintain a constant local concentration within the 
therapeutic range. 
We developed a controlled delivery system comprised of heparin and a synthetic 
polycation that interact polyvalently and phase separate from water to form sub-micron sized 
spherical droplets. These emulsion-like aggregations are referred to as a “coacervate”. Shh is 
incorporated into the coacervate by high-affinity binding to heparin and is then released in a slow 
and sustained fashion. We demonstrate that Shh delivered by the coacervate can have multiple 
beneficial effects on cardiac cells, stimulating trophic factor expression and affording 
cytoprotection from oxidative stress, and may therefore have the potential to protect the heart 
from ischemia or promote tissue regeneration following insult. This is, to the best of our 
knowledge, the first investigation of controlled delivery of Shh for cardiac repair.  
Poly(ethylene glycol) (PEG) is a suitable hydrogel material because it has variable 
stiffness based on concentration and crosslinking, and it is biologically inert [295]. We have 
previously described the structural benefit of a non-degradable PEG hydrogel, which prevented 
early LV wall thinning and dilation. However, it was unable to mitigate long-term pathological 
remodeling, likely due to chronic inflammation [296]. We were therefore motivated to develop a 
PEG gel crosslinked by peptides which were matrix metalloproteinase (MMP)-specific. The 
degradable nature of this hydrogel appeared to pacify the issue of chronic inflammation, however 
functional improvement was only observed if injection was delayed until 1 week after infarction 
[297]. On the other hand, cytoprotective therapies such as Shh will be most effective if applied as 
soon as possible after ischemic event. We therefore elected to include interleukin-10 (IL-10), an 
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anti-inflammatory cytokine that could temporarily reduce gel degradation by diminishing the 
inflammatory response to MI. 
The anti-inflammatory effects of IL-10 are due, in part, to a downregulation of IL-1β, IL-
6, and TNF-α signaling [298]. IL-10 thereby restricts macrophage activation and phagocytic 
capacity [299], and promotes their transition from the M1 to the M2 phenotype which is critical 
to enable tissue regeneration [300]. IL-10 expression in the infarcted human myocardium has 
been positively correlated with improved ventricular function [301], and direct injection of IL-10 
attenuated ventricular remodeling in mice [302]. Furthermore, heparin binds IL-10 with high 
affinity (Kd = 54 nM) and modulates its bioactivity [303], providing rationale for its delivery 
with the heparin-based coacervate alongside Shh. 
Here we describe a co-therapy of a controlled release Shh and IL-10 coacervate 
distributed within an MMP-degradable PEG hydrogel. The combination of regenerative 
molecules and a structural bulking agent has significant potential for synergistic effects. While 
the hydrogel may improve coacervate retention within the heart wall after injection, the 
regenerative environment engendered by Shh and IL-10 may improve gel integration and 
prolong its structural benefit. We evaluated this combinatorial therapy using an established in 
vivo MI model of permanent coronary ligation in rats [304].  
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4.2 MATERIALS AND METHODS 
4.2.1 Ethics statement 
Animals were cared for in compliance with a protocol approved by the Institutional Animal Care 
and Use Committee of the University of Pittsburgh, following NIH guidelines for the care and 
use of laboratory animals (NIH publication No. 85–23 rev. 1985). 
4.2.2 Shh coacervate preparation 
Poly(ethylene argininylaspartate diglyceride) (PEAD) was synthesized as previously described 
[158]. PEAD and clinical-grade heparin (Scientific Protein Labs, Waunakee, WI) were each 
dissolved in 0.9 % saline at 10 mg ml-1 and 0.22 μm filter-sterilized. Heparin was initially 
complexed with recombinant mouse Shh (N-terminus peptide; R&D Systems, Minneapolis, 
MN), then PEAD was added. Self-assembly of PEAD and heparin:Shh immediately precipitated 
the ternary complex out of solution to form the Shh coacervate. 
4.2.3 Shh coacervate imaging 
Shh was fluorescently labeled using Alexa Fluor 488 Protein Labeling Kit (Invitrogen, Carlsbad, 
CA). A fluorescently labeled Shh coacervate was prepared in water with 0.2 ng fluorescently 
labeled Shh, 100 μg heparin, and 500 μg PEAD. The coacervate was added to a 96-well plate 
and imaged using an Eclipse Ti inverted microscope (Nikon, Tokyo, Japan). 
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4.2.4 Shh release profile 
200 μl Shh coacervate containing 10 μg heparin, 100 ng Shh, and 50 μg PEAD was prepared in 
0.9% sterile saline and was then pelleted by centrifugation at 12,100 g for 5 min. The supernatant 
was aspirated and stored at -80 ⁰C and 200 μl fresh saline was replaced to cover the pellet. The 
sampling procedure was repeated on day 1, 4, 7, 10, 14, and 21 for three separate tubes. Released 
Shh in the fractions was quantified by DuoSet ELISA kit (R&D Systems) according to the 
manufacturer’s instructions. 
4.2.5 Cardiac cell isolation 
Primary cardiac cells were isolated from 1-2 day old Sprague-Dawley rat pups (Jackson Labs, 
Bar Harbor, ME). The pups’ hearts were excised aseptically and the Worthington Neonatal 
Cardiomyocyte Isolation System (Worthington, Lakewood, NJ) was used following the 
manufacturer’s instructions. Two pre-plates of 1.5 h each were used to separate cardiac 
fibroblasts (fast-adhering cells) from cardiomyocytes (slow-adhering cells). The purified 
cardiomyocyte population was seeded into 24-well plates coated with 1 μg cm-2 fibronectin 
(Millipore, Billerica, MA) at 1.5 x 105 myocytes per well for experiments. Cardiomyocytes were 
cultured in DMEM/F12 50/50 supplemented with 5 % fetal bovine serum (FBS), ITS supplement 
(Sigma, St. Louis, MO), and 100 μM 5-bromo-2′-deoxyuridine (BrdU; Sigma) to inhibit 
proliferation of any remaining fibroblasts. Cardiac fibroblasts from the first pre-plate were 
cultured in DMEM supplemented with 10 % FBS through 3 passages before use in experiments.  
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4.2.6 Immunofluorescent staining 
Immediately after isolation, purity of cardiac cell populations was analyzed by immunostaining 
using a mouse anti-myosin heavy chain (MHC) antibody (1:80, Millipore) followed by goat anti-
mouse IgG Alexa Fluor 594-conjugated secondary antibody (1:200, Invitrogen) and 
counterstained with DAPI. All images were taken using an Eclipse Ti inverted microscope 
(Nikon). 
4.2.7 Cardiac fibroblast growth factor signaling 
Isolated neonatal rat cardiac fibroblasts were used at passage 4. 5 x 104 cells were seeded per 
well in a 24-well plate and cultured to 90 % confluency. Cells were then washed once with 
DPBS and 500 μl “stimulation media” containing 1mg ml-1 Shh free or in the coacervate, or 
normal culture media was added. After 6, 12, 24, 48 h the conditioned media from two wells per 
group was removed and frozen. Indirect ELISA was run using rabbit polyclonal antibodies 
against VEGF (1:50, Peprotech, Rocky Hill, NJ), SDF-1α (1:30, Santa Cruz Biotech, Santa Cruz, 
CA), and IGF-1 (1:30, Santa Cruz Biotech). Results were normalized to total protein content, 
determined using Pierce 660 nm Protein Assay (Thermo Fisher Scientific, Waltham, MA). For 
Shh quantification, western blot was employed with samples being denatured and reduced. 
Lacking a well-accepted protein loading control for conditioned media, total protein assay results 
were used to determine appropriate loading volumes for each sample, such that 47.5 μg protein 
was loaded to each well. Following transfer, the PVDF membrane was incubated for 5 m in 
Ponceau-S staining solution (Sigma), rinsed in DI water and imaged. Immunoblotting was then 
performed using a rabbit anti-human Shh polyclonal antibody (1:200, Santa Cruz Biotech) 
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followed by a peroxidase conjugated anti-rabbit IgG antibody (Sigma). Band intensities were 
measured using NIH Image J Version 1.46r software.   
4.2.8 Cardiomyocyte oxidative stress-induced apoptosis 
Isolated cardiomyocytes were cultured for 2 d after which cells were spontaneously contracting 
at approximately 1 beat per second. Cells were pre-treated for 48 h with 500 ng ml-1 Shh or 
recombinant human fibroblast growth factor-2 (FGF2; Peprotech) as either free protein or 
delivered by the coacervate. The FGF2 coacervate was prepared similarly to the Shh coacervate. 
Cells were then exposed to 200 μM H2O2 in serum-free media to induce oxidative stress. Two 
control groups received no growth factor pre-treatment and then one received H2O2 and one did 
not. After 2 h, cells were harvested, lysed, and assayed using EnzChek Caspase-3 Kit #2 
(Invitrogen). Immediately before harvesting the cardiomyocytes, videos were taken in the center 
of the wells using an Eclipse Ti inverted microscope (Nikon) using standard light microscopy 
settings. 
4.2.9 Coacervate and PEG hydrogel preparation 
To prepare the coacervate, PEAD was synthesized as previously described [212]. PEAD and 
clinical-grade heparin (Scientific Protein Labs, Waunakee, WI) were each dissolved in DI water 
and 0.22 μm filter-sterilized. 0.33 mg Heparin was combined with 1.5 µg recombinant human 
Shh (Peprotech, Rocky Hill, NJ) and 150 ng recombinant human IL-10 (Peprotech), followed by 
addition of 1.65 mg PEAD. The coacervate was pelleted by centrifugation and the supernatant 
removed and discarded. To prepare the PEG hydrogel, vinyl sulfone-derivatized 8-arm PEG 
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(MW=20 kDa) was synthesized as previously described [296] and dissolved in PBS. MMP-1 
(GenScript, Piscataway, NJ) was dissolved in PBS, then used to re-suspend the coacervate 
thoroughly. PEG and MMP-1 solutions were combined to form 10 % w/v PEG hydrogels of 100 
µl total volume with the Shh+IL-10 coacervate homogeneously dispersed throughout.  
4.2.10 Fluorescence labeling and imaging 
The coacervate was prepared as described above, except fluorescein-labeled heparin (Creative 
PEGWorks, Winston Salem, NC) was used. The PEG hydrogel was labeled with Alexa Fluor 
660 nm dye (Life Technologies, Carlsbad, CA) as previously described [297]. Fluorescent gel 
loaded with coacervate was immersed in optimal cutting temperature (OCT) compound (Sakura 
Finetek, Torrance, CA) and 12 µm frozen sections were cut by cryomicrotome. Images were 
captured using an Eclipse Ti inverted fluorescence microscope (Nikon, Tokyo, Japan). 
4.2.11 Rat MI model 
Animals were cared for in compliance with NIH guidelines and all experiments were approved 
by the University of Cape Town’s Animal Research Ethics Committee. MI and intramyocardial 
injections were performed as we previously described [297]. Briefly, male Wistar rats (180-200 
g) underwent permanent left anterior descending coronary artery ligation using 6-0 Prolene 
suture (Ethicon, Somerville, NJ). Treatments were applied immediately as 100 µl divided into 3 
injections in evenly spaced around the infarct center thru a 31G needle. Treatment groups 
included saline (n=8), coacervate alone (n=10), PEG hydrogel alone (n=9), or gel and coacervate 
combined (n=10), and animals were randomized to the treatment groups. 
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4.2.12 Coacervate retention study 
Fluorescence-labeled coacervate was prepared as described above and was injected into infarcts 
alone (n=4 rats), or in the PEG hydrogel (n=5 rats). After 24 h the animals were sacrificed and 
their hearts explanted and frozen in OCT. 10 µm thick sections were cut every 500 µm beginning 
at the apex and continuing through the entire heart. Fluorescence images of the infarct zone were 
acquired and Image J 1.47v was used quantify the percent area positive for the coacervate as: 
Percent positive area (%) = Coacervate positive area (mm2) / Infarct zone area (mm2) * 100 %. 
Results for each animal were the average of all sections taken for that animal. 
4.2.13 Gel retention study 
Fluorescence-labeled gel was prepared as described above with or without the coacervate and 
injected into the infarct zone (n=3 rats). The animals were sacrificed after 14 days and the hearts 
were frozen in OCT and sequentially sectioned at 6 µm thickness. Sections were observed by 
fluorescence microscopy and the area positive for gel (mm2) was multiplied by the spacing 
thickness (500 µm) and summed to estimate the gel volume (mm3).  
4.2.14 Echocardiography 
Echocardiography was performed prior to surgery and on days 14 and 28 by blinded investigator 
using a Vivid i Ultrasound imaging system (GE Healthcare, Little Chalfont, United Kingdom). 
Short-axis M-mode measurements of the LV were performed and fractional shortening (FS %) 
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was calculated as: (EDD - ESD) / EDD * 100 % (EDD=end-diastolic diameter, ESD=end-
systolic diameter).  
4.2.15 Histological analysis 
Rats were sacrificed on day 28 and their hearts removed, rinsed in PBS, and fixed in 10 % 
formalin for 24 h. Hearts were processed through graded alcohol and xylene, paraffin-embedded, 
and 3 µm sections cut and then de-waxed. Heart sections were stained by Masson’s trichrome as 
previously described [297].  
4.2.16 Statistical analysis 
Statistical analysis was performed using SPSS 16.0 software (SPSS Inc, Chicago, IL). Data was 
tested for normality and equal variance before analysis. Statistical differences between groups 
were calculated using one-way analysis of variance (ANOVA) followed by Tukey post-hoc 
testing. Differences were considered significant at P<0.05. 
4.3 RESULTS 
4.3.1 Shh coacervate characterization and release 
Fluorescent imaging of the Shh coacervate revealed round droplets ranging from 0.5-10 μm in 
size (Fig. 22). Shh release from the coacervate into saline was sustained for at least 3 weeks with 
80% being released in total (Fig. 23). Less than 5% Shh was detected in the supernatant 
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immediately after forming the coacervate and pelleting, therefore loading efficiency is greater 
than 95%. There was effectively no initial burst release. Of the 100 ng loaded, approximately 6 
ng day-1 was released until day 10, then slowing to around 2 ng day-1 until day 21. 
 
 
 
Figure 22. Shh coacervate imaging.  Alexa Fluor 488-labeled Shh was incorporated into the coacervate in 
water and imaged by fluorescence microscopy. (a) 10X magnification. (b) 40X magnification. Scale bars = 100 μm. 
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Figure 23. Shh release profile.  In vitro release of Shh from the coacervate into saline over 21 days, 
quantified by sandwich ELISA. Percent release is relative to total amount loaded. Bars indicate means ± SD. 
 
4.3.2 Shh coacervate upregulates growth factor secretion by cardiac fibroblasts 
Isolated neonatal rat cardiac fibroblasts were stimulated with Shh, free or in the coacervate, and 
analyzed for expression of various growth factors over 2 days. Shh itself was detected in 
increasing concentrations, up to 7.8 times the initially added amount by 48h (Fig. 24a). VEGF, 
SDF-1α, and IGF-1 were at 2- to 4-fold higher levels by 6 hours after stimulation with both free 
Shh and Shh coacervate and remained upregulated for 48 h (Fig. 24b-d). The VEGF level at the 
6 hour timepoint stimulated by Shh coacervate was significantly greater than that stimulated by 
free Shh. Conditioned media from cells treated with normal culture media had undetectable 
concentrations of all growth factors tested at every timepoint (data not shown). 
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Figure 24.  Shh-stimulated cardiac fibroblast signaling.   Near-confluent cardiac fibroblasts were 
incubated with Shh, free or in the coacervate, and growth factor levels in the conditioned media were assessed after 
6, 12, 24, and 48h.  Data is presented as a fold-change from the stimulation media (C). Bars indicate means ± SD. 
(a) Quantification of Shh concentration in the cardiac fibroblast-conditioned media by western blot. Ponceau-S 
staining of protein bands near 27 kDa is shown as the loading control.  (b) Quantification of VEGF in the cardiac 
fibroblast-conditioned media by indirect ELISA, *P<0.05. (c) Quantification of SDF-1α in the cardiac fibroblast-
conditioned media by indirect ELISA. (d) Quantification of IGF-1 in the cardiac fibroblast-conditioned media by 
indirect ELISA.  
 
4.3.3 Shh coacervate protects cardiomyocytes from apoptosis 
Caspase-3 is a well-known indicator of cell apoptosis due to oxidative stress, mimicked here 
with 200μM H2O2 in culture media. This concentration of H2O2 is higher than has been 
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previously reported to induce myocyte apoptosis [305]. Cardiac cell isolation yielded a highly 
pure population of primary neonatal rat cardiomyocytes (Fig. 25).  
 
 
 
Figure 25. Neonatal rat cardiac cell populations were separated by pre-plate technique.  Slow-
adhering cardiomyocytes did not adhere to the pre-plate while fast-adhering cardiac fibroblasts did adhere. Both 
populations were immunofluorescent stained for myosin heavy chain (MHC) muscle cell marker (red) and 
counterstained with DAPI for cell nuclei (blue). Scale bars = 100 μm. 
 
 
Myocytes pre-treated with FGF2 coacervate or Shh coacervate showed significantly 
lower levels of apoptosis compared to the H2O2 treated control, but higher levels than the control 
group not treated with H2O2 (Fig. 26). Additionally, the difference in means compared to the 
H2O2 treated control was more statistically significant for Shh coacervate than for FGF2 
coacervate (p=0.003 vs. p=0.012). Incubation with free FGF2 or Shh did reduce caspase-3 levels, 
however these differences were not statistically significant (p=0.094 and p=0.083) from the H2O2 
treated control. Videos taken at the experiment endpoint show that cardiomyocytes were beating 
normally in the non-H2O2 treated control, but rapidly and irregularly in the Free Shh group and 
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Shh coacervate group. Additionally, more cells were beating in the Shh coacervate group than in 
the Free Shh group in accordance with our caspase-3 results. 
 
 
 
Figure 26.  Cytoprotection of cardiomyocytes from oxidative stress-induced apoptosis.   Myocytes 
were pre-treated for 48h with FGF2 or Shh, free or delivered in the coacervate. Cells were then exposed to oxidative 
stress conditions with H2O2 for 2h. Two control groups were not pre-treated with any growth factors and then one 
received H2O2 for 2h (+) and one did not (-). Cell apoptosis levels were measured by caspase-3 activity. *P<0.05, 
**P<0.01 compared to the +H2O2 control group. 
 
4.3.4 Fluorescence imaging of Gel+Coacervate 
To ensure the coacervate and PEG gel were compatible we began by fluorescence-labeling each 
and formed the gel ex vivo. Fluorescence microscopy indicated that the coacervate was 
homogenously distributed throughout the gel with an embedded appearance and consisted of 
spherical droplets with diameters ranging from approximately 0.5-10 µm, consistent with our 
previous reports [166] (Fig. 27).  
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Figure 27.  Fluorescence-labeled PEG gel and coacervate.  PEG gel was labeled with AlexaFluor 660 
dye (red) and the coacervate was labeled with fluorescein (green). Scale bars = 100 µm. 
 
4.3.5 Gel improves coacervate retention after myocardial injection 
We next wanted to test the effectiveness of the PEG gel at improving the retention of the 
coacervate after injecting into the heart wall. We created MI in rats by permanent left anterior 
descending (LAD) ligation, then injected the fluorescence-labeled coacervate alone or dispersed 
within the PEG gel. One day after injection we observed a much lower fluorescence signal when 
applied alone (Fig. 28a) compared to in the PEG gel (Fig. 28b). The coacervate also had a vastly 
different appearance in each case; when injected alone it had a punctated morphology and when 
in the gel it looked striated. The gel appeared to have been forced into interstices between 
myocytes and the coacervate congealed and followed the contours of the gel, thus resembling the 
morphology we described previously [297].  We also quantified the area of the infarct region that 
was positive for fluorescent coacervate signal and found it to be 3-fold higher when the gel was 
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used (Fig. 28c). These data demonstrate that the gel increases coacervate retention and spreading 
within the myocardium. 
 
 
 
Figure 28.  Coacervate retention 1 day post-injection.  The coacervate was fluorescence-labeled (green) 
and infarcted rat hearts were injected with a) Coacervate only or b) Gel+Coacervate. Animals were sacrificed after 
24 h and the coacervate was identified by fluorescence microscopy. Dotted lines indicate the outer boundary of the 
left ventricular wall. Scale bars = 100 µm. c) Percent area of the heart positive for coacervate. Bars indicate means ± 
SD of 4-5 rats per group. **p<0.01. 
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4.3.6 Coacervate improves gel integration after myocardial injection 
We were also interested in the effect of the coacervate on the gel residence time in the 
myocardium. We created infarcts and injected the fluorescence-labeled PEG gel either with or 
without the coacervate, then observed the gel by fluorescence microscopy after 2 weeks. We 
observed numerous regions of gel without the coacervate remaining after 2 weeks that were 
completely acellular, indicating incomplete acceptance of the material by the body (Fig. 29a). In 
contrast, the gel containing the coacervate was evenly distributed throughout the wall and had 
much higher cell infiltration (Fig. 29b). We estimated the total volume of gel remaining by 
quantifying the fluorescence area in sequential sections thru the entire infarct. These results 
revealed a trend towards more gel remaining when injected without than with the coacervate, 
though this difference was not statistically significant (p=0.39) (Fig. 29c). Taken together, these 
data indicate that the coacervate does promote integration of the gel into the myocardial wall. 
Although this generally leads to bulk rather than surface degradation which should increase the 
local degradation rate as the trend suggests, the coacervate may not significantly affect the 
overall rate of gel degradation. Consequently, no gel was observed in hearts from either group 
after 4 weeks. These results were surprising because we predicted that IL-10 released from the 
coacervate would suppress the inflammatory response towards the gel, thereby prolonging its 
residence. However, Shh has been shown to upregulate cardiac fibroblast expression of stromal-
cell derived factor-1α, a stem cell homing chemokine [163]. This may result in a larger stem cell 
presence which enhance the regenerative environment but also secrete MMPs and may 
contribute to polymer degradation [306]. 
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Figure 29.  Gel integration 2 weeks post-injection.  The gel was fluorescence-labeled (purple) and 
infarcted rat hearts were injected with a) Gel only or b) Gel+Coacervate. After 14 days the animals were sacrificed 
and the gel was identified by fluorescence microscopy in sections co-stained with DAPI for cell nuclei (blue). 
Indicated regions of the left column are magnified in the right column. Scale bars = 500 µm. c) Gel volume 
quantified in the infarct region. Bars represent means ± SD of 3 rats per group.  
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4.3.7 Gel+Coacervate preserves heart function after MI 
We next assessed the synergistic benefits of the gel and coacervate towards heart function 
following MI. We performed LAD coronary ligation in rats, then immediately injected the 
therapy at 3 locations, evenly spaced around the infarct zone. Echocardiography performed after 
2 and 4 weeks revealed a higher fractional shortening with the combined gel and coacervate 
treatment compared to all other groups, and these differences were statistically significant at both 
timepoints (Fig. 30). Either therapy alone showed no significant benefit over the saline control 
group. This is consistent with our previous report that the PEG gel alone has no significant effect 
on heart function when injected immediately after infarction [297]. As in our previous study, 
delayed injections of the combined gel and coacervate performed 1 week after MI also resulted 
in functional benefit, and furthermore it was not significantly different from immediate injection 
(Fig. 31). These results demonstrate that the gel and coacervate is still effective when applied 
within this 1 week timeframe which may have greater clinical relevance than immediate 
injection [307]. The ineffectiveness of the coacervate alone is likely due to the low retention after 
injection without the support of the gel. Taken together, these results indicate that the synergism 
between the gel and coacervate is vital to its successful preservation of heart function after MI.  
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Figure 30.  Functional analysis.  Rat infarcts were injected with saline, coacervate alone, gel alone, or the 
combined gel and coacervate. Echocardiography was performed prior to MI (baseline) and 2 and 4 weeks after MI, 
and data presented as fractional shortening. Bars indicate means ± SD of 8-10 rats per group. *p<0.05, **p<0.01 
compared to all other groups. 
 
 
 
Figure 31.  Effect of Gel+Coacervate injection timing on cardiac function.  Rat infarcts were injected 
with Gel+Coacervate immediately or 1 week after infarction (delayed). Echocardiography was performed prior to 
MI (baseline) and 2 and 4 weeks after MI, and data presented as fractional shortening. Bars indicate means ± SD of 
n=10 for Immediate group and n=3 for Delayed group. 
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4.3.8 Gel+Coacervate reduces scar burden  
Fibrotic scar formation is often the main factor leading to reduced cardiac function and 
eventually congestive heart failure. We observed the dense collagen-rich scar tissue of the rat 
infarcts after 4 weeks using Masson’s trichrome staining. Hearts receiving the combined gel and 
coacervate treatment had a noticeably smaller scar region compared to other groups; however, 
there appeared to be no obvious difference between groups in the heart wall thickness of the scar 
region (Fig. 32a-d). Quantification of the scar burden, the percent of the heart circumference 
containing scar, revealed a lower mean value with the combined treatment compared to other 
groups, although these differences were not statistically significant (Fig. 32e). As observed, there 
were also no statistically significant differences in wall thickness between groups, though the 
saline group had the lowest mean value (Fig. 32f). Fibrosis occurs to replace voids left by 
cardiomyocyte death, thus the two are directly correlated [308]. Shh can reduce oxidative stress 
on myocytes directly or indirectly through upregulation of IGF-1 [163]. Therefore animals 
receiving the coacervate likely experienced lower levels of myocyte apoptosis which reduces 
fibrotic scarring; differences between these groups can be attributed to greater coacervate 
retention with the gel than without.  
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Figure 32.  Scar burden and wall thickness.  Masson’s trichrome staining was performed 4 weeks after 
MI to observe fibrosis in hearts treated with a) Saline, b) Coacervate only, c) Gel only, d) Gel+Coacervate. 
Collagenous scar tissue appears blue and healthy muscle appears red. Bars indicate means ± SD of 8-10 rats per 
group. 
 
4.3.9 Coacervate induces robust angiogenesis 
Vascularization plays a key role in promoting a pro-healing environment by delivery the 
necessary oxygen, nutrients, and progenitor cells and removing waste. Because the primary 
supply is cut off during ischemia, angiogenesis must occur from neighboring vessels to gradually 
reperfuse the tissue. Shh has been shown to play a role in angiogenesis by upregulating local 
 114 
expression of vascular endothelial growth factor and angiopoeitin-1 [164] and by enhancing the 
contribution of blood-derived endothelial progenitor cells [309]. We investigated the vascularity 
within the infarct zone to elucidate the effect of our treatments on angiogenesis or the survival of 
pre-existing vessels. Animals utilized for the gel retention study provided an indication of 
vascularization at 2 weeks post-MI in groups receiving the gel (Fig. 33a,b). We observed 
significantly more blood vessels in hearts also receiving the coacervate compared to the gel alone 
(Fig. 33c). In the early timeframe after MI, more vessels in groups receiving the co-therapy 
explains in part the reduced fibrosis and better cardiac function. At 4 weeks post-MI we observed 
nearly 3-fold the number of vessels in hearts treated with coacervate alone (16.3±2.2) compared 
to saline (6.1±0.9), and the addition of the gel did not significantly alter the angiogenic effect of 
the coacervate alone (Fig. 33d). Surprisingly, the gel alone also showed a higher number of 
vessels per volume infarct at 4 weeks, though like the co-therapy, this was not a statistically 
significant difference from saline. Perhaps a late inflammatory response to the gel resulted in 
increased growth factor and cytokine expression in the infarct region by macrophages. We also 
observed a similar trend of treatment effect on blood vessel numbers in the border zone 
surrounding the infarct, though the numbers were significantly less than within the infarct (Fig. 
34). These results indicate that the effects of the coacervate can propagate beyond the application 
area either by growth factor translocation via the extracellular matrix, or indirectly through 
paracrine signaling.  
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Figure 33.  Blood vessel quantification.  Mature blood vessels were identified by α-smooth muscle actin 
immunohistochemical staining for smooth muscle cells. Representative images from within the infarct region 2 
weeks post-MI, treated with: a) Gel only, or b) Gel+Coacervate. Scale bars = 100 µm. c) 2 week blood vessel 
quantification. Bars indicate means ± SD of 3 rats per group. *p<0.05. d) 4 week blood vessel quantification. Bars 
indicate means ± SD of 8-10 rats per group. *p<0.05. 
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Figure 34.  Border zone blood vessel quantification.  Mature blood vessels were identified by α-smooth 
muscle actin immunohistochemical staining for smooth muscle cells. Blood vessels were quantified at the 4 week 
timepoint in the border zone surrounding the infarct. Bars indicate means ± SD of 8-10 rats per group. *p<0.05. 
 
4.4 DISCUSSION 
Ischemic damage to the heart may be mitigated by Shh through three key mechanisms: i) 
Angiogenesis- the sprouting of new blood vessels from pre-existing ones, ii) Cytoprotection of 
cardiomyocytes under oxidative stress, and iii) Recruitment of cardiac progenitor cells. 
Shh-induced neovascularization is a result of upregulated paracrine signaling by 
fibroblasts of several angiogenic factors including vascular endothelial growth factor (VEGF) 
and angiopoetin-1 [164, 309, 310]. It has also been shown to increase the contribution of bone 
marrow-derived endothelial progenitor cells (EPCs) to the neovascularization process [309, 311, 
312]. Additionally, recent reports have revealed that Shh acts through the Rho-associated protein 
kinase (ROCK) pathway, rather than its traditional Gli-dependent pathway, to stimulate 
expression of matrix metalloproteinase-9 (MMP-9) and osteopontin (OPN) in endothelial cells 
[313, 314]. These multiple complex roles of Shh underscore its importance in ischemic 
 117 
revascularization. In the present work we show that the Shh coacervate can stimulate cardiac 
fibroblasts to significantly upregulate expression of VEGF. Furthermore, Shh coacervate acutely 
(6 hour timepoint) stimulated significantly more VEGF production than free Shh. This may be 
attributed to enhanced morphogen bioactivity when delivered by the coacervate, as discussed 
later. In vivo, this upregulated angiogenic growth factor expression may induce angiogenesis to 
re-vascularize the ischemic myocardium.  
The cytoprotective effects Shh displays for cardiomyocytes have also been attributed to 
multiple mechanisms. One contributor is insulin-like growth factor (IGF-1) which has been 
shown to be upregulated in Shh-stimulated cardiac fibroblasts [163] and bone marrow-derived 
cells [315]. IGF-1 interferes with the transcription of angiotensin II, thereby preventing the 
formation of reactive oxygen species during oxidative stress [316, 317]. A more direct anti-
apoptotic role of Shh has also been demonstrated in vitro for cardiomyocytes, which express the 
Shh receptor Patched-1 [163].  Our results seem to confirm this direct role, as recombinant Shh 
protein applied alone to stressed cardiomyocytes reduced cell apoptosis. Yet we must still 
consider that the cardiomyocyte population was not entirely pure and may have contained a 
small number of fibroblasts. Upregulated secretion of IGF-1 by these fibroblasts may have 
therefore played a role as well. FGF2 was included as a positive control in apoptosis experiments 
as it is a well-known survival factor for numerous cell types [318-320] including cardiomyocytes 
[321], and we have experience delivering it with the coacervate [21, 160, 322]. We observed the 
coacervate to enhance the bioactivity of both FGF2 and Shh compared to either factor in free 
form. We also found that Shh coacervate protected stressed cardiomyocytes better than FGF2 
coacervate. This is significant because FGF2 expression by fibroblasts has actually been shown 
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to be downregulated in response to Shh stimulation [164]. The anti-apoptotic effects of Shh must 
therefore be ascribed to non-FGF2-related pathways.  
Stromal cell-derived factor-1 (SDF-1), also known as CXCL12, is a trafficking 
chemokine for stem and progenitor cells [323]. It has been shown to act in local recruitment of 
cardiac progenitor cells [324-326], as well as EPCs [327] and smooth muscle progenitor cells 
[328]. It is well accepted that SDF-1  plays a pivotal role in stem and progenitor cell homing to 
sites of injury [329]. We prove here that Shh coacervate can upregulate production of SDF-1α at 
least as well as equal dose of free Shh, therefore the bioactivity of released Shh is well 
maintained. In vivo, high local levels of SDF-1α may encourage recruitment of blood derived 
EPCs to aid in neovascularization, and of cardiac progenitor cells to engender myocardial tissue 
repair. 
Clearly, Shh acts as a “master switch” agent in many tissues including the heart, 
activating multiple downstream pathways in response to injury. Shh has been shown to activate 
the ERK1/2 [330], PKC [165], ROCK [313], and PI3K/Akt [311] signaling pathways, among 
others. Shh morphogen may therefore provide benefits similar to co-delivery of multiple 
different growth factors. However, a multi-factor approach would require extensive optimization 
of growth factor dosage and release rate, while Shh stimulates a natural healing environment, 
similar to the embryonic state when cardiac regeneration is possible. Finally, we also observed 
upregulated Shh expression by cardiac fibroblasts in response to stimulation with Shh, a positive 
autoregulation that has been previously reported [163].  
Regarding the role the coacervate plays in enhancing the effects of Shh, we point to 
heparin as a major player. Proteoglycans associated with the extracellular matrix or cell surface 
play a vital role in the transduction of cell signaling pathways [331]. Heparin binds many growth 
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factors, cytokines, and morphgens, stabilizes and protects them, and in some cases modulates 
their activity [260, 332]. It has been shown to interact with a growth factor molecule and its 
corresponding cell receptor simultaneously, forming a stable ternary complex which facilitates 
signal activation [12]. Heparan sulfate proteoglycans have also been shown to play a vital role in 
developmental patterning and specifically in regulating Hedgehog distribution and pathway 
activation [333, 334]. Heparin binds Shh with high affinity (Kd = 99nM) [335] and may 
inherently enhance its bioactivity by mimicking the in situ signaling environment. Indeed, the 
biological activity of Shh has been shown to be directly related to its affinity for heparin [335]. 
We suggest that utilizing heparin in our delivery system may thereby potentiate the activity of 
Shh. This is supported by our previous reports using the coacervate to deliver FGF2 [160, 322], 
neuronal growth factor [21], and heparin-binding EGF-like growth factor [141]. However, the 
efficacy of the coacervate at maintaining or enhancing the bioactivity of Shh in an in vivo 
environment requires further evaluation. 
The activity of bound factors is further preserved within the coacervate, which is in a 
separate phase from water. This isolation provides further protection from proteases. The 
heparin:Shh complex is soluble in water and if injected in vivo would therefore be quickly 
diluted and removed from the injection site. To maintain the complex locally, an insoluble 
coacervate is formed using a synthetic polycation, PEAD. This ariginine-based polycation was 
designed to imitate the highly cationic heparin-binding domain [12]. Heparin-bound factors are 
incorporated into the coacervate and protected from proteolysis and denaturation. Release from 
the coacervate is based on slow hydrolysis of the polycation [158], as well as dissolution of the 
complex in an ionic environment. We expect the release of Shh from the coacervate to be 
accelerated in vivo in in the presence of enzymes. We have previously shown this polycation to 
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be highly biocompatible and to complex with heparin to control the release of many different 
growth factors [158]. The results presented here suggest that a simple liquid coacervate has high 
potential as a system of controlled delivery for heparin-binding morphogens, in addition to 
growth factors. 
4.5 CONCLUSIONS 
The results of this study indicate that PEAD-heparin coacervate can load Shh with high 
efficiency and sustain its release for at least 21 days. Shh released from the coacervate displays 
bioactivity equal to or higher than that of free Shh. We demonstrate the ability of Shh coacervate 
to protect cardiomyocytes from oxidative stress and to upregulate secretion of multiple growth 
factors by cardiac fibroblasts. These results warrant further investigation of Shh coacervate for 
treating cardiac ischemia. 
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5.0  CONTROLLED DELIVERY OF BMP-2 TO IMPROVE STEM CELL THERAPY 
FOR BONE REGENERATION 
5.1 INTRODUCTION 
The existence of osteoprogenitor cells in the skeletal muscle has long been postulated 
[336-340]. A number of candidates have been proposed, such as satellite cells [341] and primary 
myoblasts [341, 342]. Our group has also isolated and characterized a slowly-adherent cell 
population (MDSCs) from skeletal muscle via a modified pre-plate technique [343-346]; 
however, their exact relationship to satellite cells and blood vessel derived progenitor cells 
remains unclear [347]. When provided with osteogenic stimuli such as BMPs, they can produce 
osseous-like tissue in vitro [341, 343], and when retrovirally transduced to express BMP2 or 
BMP4 have been shown to differentiate into osteocytes and chondrocytes and enhance bone and 
articular cartilage repair in vivo [344, 348-352]. More importantly, BMP-transduced MDSCs 
show superior bone healing capabilities compared to other similarly transduced muscle-derived 
cells [353, 354]. These reports suggest that progenitor cells derived from skeletal muscle, 
especially MDSCs, could be a promising alternative cell source to bone marrow derived 
mesenchymal stem cells (BMSCs) for bone tissue engineering.  
Despite the promise that MDSCs hold for bone regeneration, without the presence of 
BMPs they do not differentiate towards an osteogenic lineage, rather they form myotubes and 
 122 
myofibers when injected alone into a muscle pocket [340, 355, 356]. Applying the proper stimuli 
to create an osteoinductive environment in vivo is therefore important for harnessing the 
osteogenic potential of MDSCs. BMP2 and BMP4 have been shown to produce the most 
successful results using gene transduction [344, 350-352]; however, from a translational point of 
view, a non-viral approach is preferred, and thus far has received limited exploration.  
It is known that prolonged exposure to BMPs at an appropriate concentration is necessary 
to induce MDSC differentiation and subsequent osteo-chondrogenesis in vivo; however, BMPs 
have very short half-lives in the body [357, 358], and maintaining an adequate local BMP 
concentration is challenging. A controlled delivery method that can protect and sustain the 
release of BMPs would be particularly attractive for muscle cell-based bone engineering. To this 
end, we employed a recently developed growth factor delivery platform comprised of native 
heparin and a synthetic polycation, poly(ethylene argininylaspartate diglyceride) (PEAD), to 
deliver BMP. In this delivery platform, heparin tightly binds BMP2 via its high-affinity heparin 
binding site and then PEAD interacts with heparin by polyvalent charge attraction (Fig. 1). The 
polycation-heparin complex loaded with BMP2 self-assembles into a coacervate, held together 
by Coulombic forces. A coacervate is an emulsion-like aggregation of organic molecules 
separated from the aqueous phase. The PEAD-heparin coacervate contains spherical droplets 
ranging from 10-500 nm in diameter [359]. We have previously shown that this controlled 
release platform can effectively deliver fibroblast growth factor-2 (FGF2) for therapeutic 
angiogenesis [211]. The coacervate delivery vehicle displayed nearly 100% loading efficiency, 
minimal burst release, and potentiated the bioactivity of released FGF2 [211]. In this study, we 
employ the use of this PEAD-heparin coacervate delivery system to obtain a constant release of 
BMP2 in a temporally- and spatially-controlled manner in order to promote osteogenesis by 
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MDSCs. We hypothesized that the coacervate delivery system could effectively stabilize, 
localize, and sustain the release of BMP2, to sufficiently stimulate MDSCs to undergo 
osteoblastic lineage differentiation in vitro and to form bone at an ectopic site in vivo (Fig. 35).  
 
 
 
Figure 35.  Schematic diagram of ectopic bone formation model in vivo.  Heparin and BMP2 are 
combined initially to allow growth factor binding. Then PEAD, a polycation bearing 2 positive charges per 
repeating unit, is added which interacts with heparin (a polyanion) by polyvalent charge attraction. This induces 
self-assembly of nanometer-sized coacervate droplets, separate from the aqueous phase and incorporating the BMP2 
molecules. The coacervate is then mixed with MDSCs, suspended in a fibrin gel and pipetted into a quadricep 
muscle pocket created in the hind limbs of mice. The implantation site is evaluated after 2 and 4 weeks for ectopic 
bone formation by MDSCs stimulated by the BMP2 coacervate. 
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5.2 MATERIALS AND METHODS 
5.2.1 Preparation of the BMP2 coacervate 
Poly(ethylene argininylaspartate diglyceride) (PEAD) was synthesized as previously described 
[212, 213]. Clinical-grade Heparin Sodium, USP from porcine intestine (Scientific Protein Labs, 
Waunakee, WI) and PEAD were each dissolved in saline at 0.125mg/ml and filter-sterilized at 
0.22μm. Heparin and recombinant human BMP2 (Medtronic, Fridley, MN) were combined 
initially and pipetted to mix and allow for growth factor binding. PEAD was added at a 5:1 
PEAD:heparin mass ratio, previously shown to produce an overall neutrally-charged 
solution[213]. The BMP2 coacervate formed immediately upon addition of PEAD, visible as a 
turbid solution. The BMP2 coacervate was then added by pipet to cell culture media for in vitro 
testing, or suspended in fibrinogen solution for in vivo implantation.  
5.2.2 BMP2 loading and release assays 
The BMP2-coacervate was formed with 100μg heparin, 100ng BMP2, and 500μg PEAD in 
Dulbecco’s phosphate buffered saline (DPBS) and centrifuged at 12,100 x g for 5 min to pellet 
the coacervate. For determination of loading efficiency, western blot was performed by mixing 
the supernatant and pellet with sample buffer followed by denaturation at 95°C for 5min. The 
proteins were separated by SDS-PAGE and then transferred to a PVDF membrane. Rabbit anti-
human BMP2 primary antibody (PeproTech, Rocky Hill, NJ) and HRP-conjugated anti-rabbit 
IgG secondary antibody (Sigma-Aldrich, St. Louis, MO) were used, followed by the addition of 
a chemiluminescent substrate (Thermo Fisher Scientific, Waltham, MA). Band intensities were 
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quantified using ImageLab software (Bio-Rad, Hercules, CA) and compared to a standard band 
of 100ng free BMP2 in DPBS for calculation of loading efficiency. To determine the release 
profile, media supernatant was aspirated at various time points and replaced with fresh DPBS 
and incubated at 37⁰C. BMP2 levels in the supernatant were quantified by BMP2 ELISA kit 
(PeproTech). 
5.2.3 Isolation, culture, and transduction of mouse MDSCs 
MDSCs were isolated from the hind limb skeletal muscle of 3 week old C57/BL10J mice 
(Jackson Labs, Bar Harbor, ME) via a modified pre-plate technique that has been described 
previously [343-345]. MDSCs were cultured on collagen I-coated flasks in MDSC basal media, 
defined as Dulbecco’s Modified Eagle’s Medium (DMEM) supplemented with 10% fetal bovine 
serum (FBS), 10% horse serum, 1% penicillin/streptomycin (all from Invitrogen, Carlsbad, CA), 
and 0.5% chick embryo extract (CEE; Accurate, Westbury, NY). Cells were trypsinized and 
replated at a density of 250 cells/cm2 until a sufficient number of cells were available for the 
assays. For in vivo cell tracking, MDSCs were retrovirally transduced with a green fluorescent 
protein (GFP) vector as described previously[360]. The transduced cells were sorted for GFP 
signal by fluorescence-activated cell sorting (FACSAria; BD Biosciences, San Jose, CA) and 
cultured for 2 passages prior to use in the experiments.  
5.2.4 In vitro MDSC proliferation assay  
Cell growth over time was assessed by DNA quantification assay as described previously[361]. 
Briefly, 2×103 MDSCs were seeded in a 48-well plate in MDSC basal medium and incubated 
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overnight. The next day, the medium was replaced with MDSC basal medium supplemented 
with 0 (control), 0.125, 0.25, or 0.5mg/ml coacervate (PEAD:heparin). The coacervate was 
prepared by dissolving PEAD and heparin in DPBS and then combining them at a 5:1 
PEAD:heparin mass ratio. Appropriate volumes of pre-formed coacervate were then added to the 
media at the desired concentrations. On days 1, 3, and 5, cell lysates were prepared by the 
addition of 0.1% Triton X-100 (Sigma-Aldrich) followed by 3 freeze-thaw cycles. Double-
stranded DNA (dsDNA) content of the cell lysate was measured using a Quant-iT dsDNA high-
sensitivity assay kit (Invitrogen). 
5.2.5 In vitro assays of osteogenic potential of C2C12 cells and MDSCs 
The bioactivity of delivered BMP2 was determined by its ability to stimulate alkaline 
phosphatase (ALP) production by a mouse myoblast cell line, C2C12 (CRL-1772; ATCC, 
Manassas, VA), in monolayer culture. The osteogenic effects of delivered BMP2 were also 
evaluated in vitro by ALP expression of the MDSCs in both monolayer and 3-D culture within a 
fibrin gel. Briefly, for monolayer culture the cells were seeded in a 24-well plate in MDSC basal 
media and a cell culture insert (BD Biosciences) with 0.4μm pores was placed in each well. 
100ng free BMP2 or BMP2 coacervate was added to the media in the insert. For the multi-dose 
group, 100ng free BMP2 was added on days 0, 2, and 4, for a total of 300ng BMP2. Cells were 
cultured for 5 days, followed by ALP activity quantification, ALP staining, and real-time 
reverse-transcription (RT) PCR analysis for the osteogenic markers Runx2 and Collagen type I. 
BMP4-transduced MDSCs, which have been shown to undergo osteogenesis both in vitro and in 
vivo, served as a positive control[344, 348-352]. For 3-D culture, 100ng free BMP2 or BMP2 
coacervate was suspended in serum-free MDSC basal medium containing 10mg/ml dissolved 
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bovine fibrinogen (Sigma-Aldrich) and used to resuspend 2×105 MDSCs. 9.5 NIH U/ml 
thrombin (Sigma-Aldrich) in 2.5mM CaCl2 (aq.) was then added, mixed briefly by pipet, moved 
to a 96-well plate and solidified at 37°C to form a 100μl gel. Finally, 100μl of MDSC basal 
medium was overlaid on each gel. After 5 days of culture, fibrin gels were disassociated using a 
rotor-stator type homogenizer (IKA, Wilmington, NC) and ALP activity of MDSCs was 
quantified. Briefly, cells were lysed with 0.1% Triton X-100 and subjected to three freeze-thaw 
cycles. Cell debris was removed by centrifugation, and 10μl supernatant was transferred to a 96-
well plate. 100μl Alkaline Phosphatase (pNPP) Liquid Substrate (Sigma-Aldrich) was added and 
incubated at room temperature for 15min in the dark. The reaction was stopped with 50μl of 3N 
sodium hydroxide and the absorbance at 405nm was measured by spectrophotometer (Infinite 
M200; Tecan, Männedorf, Switzerland). ALP activity was normalized by total DNA content, and 
quantified as described above. The ALP expression patterns of the cultured cells were observed 
by ALP staining (86C-1KT, Sigma-Aldrich) following the manufacturer’s instructions. For RT-
PCR, cellular RNA of MDSCs was extracted using an RNeasy Mini Kit (Qiagen). Aliquots of 
1μg total RNA were hybridized with random primers and converted into cDNA using a 
SuperScript First-Stand Synthesis System (Invitrogen). Real time PCR was performed on an 
iCycler iQ5 PCR machine (BioRad) using SYBR Green Master mix (Thermo Scientific). The 
gene-specific primer sets (Runx.2: Forward-GACTGTGGTTACCGTCATGGC, Reverse- 
ACTTGGTTTTTCATAACAGCGGA; COL1A1: Forward- GCTCCTCTTAGGGGCCACT, 
Reverse- ATTGGGGACCCTTAGGCCAT; β-actin: Forward- AGCGGGAAATCGTGCGTG, 
Reverse- CAGGGTACATGGTGGTGCC) were used at a final concentration of 0.3μM. All real 
time PCR assays were performed in triplicate. Gene expression was calculated using the relative 
 128 
standard curve method. Expression of the specific markers were normalized to β-actin and then 
scaled according to the control sample, for which the value was set to 1. 
5.2.6 In vivo bone formation at a heterotopic site  
University of Pittsburgh Institutional Animal Care and Use Committee (IACUC) approval was 
obtained prior any animal studies being performed. Power analysis was based on a pilot study 
performed under identical conditions but with different treatment groups which all contained 
MDSCs and BMP2 in a fibrin gel. The pooled standard deviation of bone volume after 4 weeks 
of healing was 1.032mm3 for this pilot study (unpublished data). A power analysis calculation 
indicated that in order to detect 1.5 standard deviations of the variable means (α-error=0.05, β-
error=0.2), 6 ectopic sites per group were required (Minitab). Thus, fifteen 6-8 week old 
C57/BL10J mice were randomly allocated into 5 groups: Control (no cells, no coacervate), 
MDSCs only, BMP-2 coacervate only, Free BMP-2+MDSCs, and BMP-2 coacervate+MDSCs. 
Mice were anesthetized with isoflurane and a 1cm incision was made on the lateral aspect of 
both thighs (6 thighs per group). The quadricep muscles were identified and a small incision was 
made and held open with forceps. Immediately before implantation, 2μg of free BMP2 or BMP2 
coacervate (2µg BMP2, 40µg heparin, and 200µg PEAD) and 5×105 MDSCs were suspended in 
40μl of 10mg/ml fibrinogen solution, and combined with 9.5 NIH U/ml thrombin. The solution 
was pipetted into the open muscle pocket where it conformed to the pocket space and was 
allowed to solidify briefly, forming the fibrin gel. The incision was then closed with 4-0 Prolene 
suture. The animals were examined radiographically 2 and 4 weeks after implantation and 
histologically at week 4. No immune-suppressive treatment was given as the MDSCs were 
isolated from C57/BL10J mice from the same inbred colony.  
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5.2.7 In vivo bone formation of human MDSCs 
University of Pittsburgh Institutional Animal Care and Use Committee (IACUC) approval was 
obtained prior any animal studies being performed. 5x105 hMDSCs were suspended in fibrin 
glue with 2µg of BMP2 (free BMP2+hMDSCs) or via the coacervate delivery system containing 
2µg of BMP2 (BMP2 coacervate+hMDSCs) and transplanted into a skeletal muscle pocket or 
into a 5mm critical-sized cranial defect created in CD1 (nude) mice (Jackson Labs). 
5.2.8 Radiographical and histological analysis 
At each time point, animals were anesthetized by inhalation of isoflurane. Both thighs were 
scanned with a Micro-CT scanner (VivaCT 40; Scanco, Brüttisellen, Switzerland) and the 
mineralized bone tissue within the muscle pocket was quantified. The Micro-CT scanning and 
quantification of the mineralized bone volume were performed by a specialist in the laboratory 
who was blinded to the group design. Following sacrifice, quadricep muscles were removed, 
fixed in 4% paraformaldehyde, embedded in sodium carboxy methyl cellulose (CMC)  (NEG50; 
Richard-Allan Scientific, Kalamazoo, MI), frozen in liquid nitrogen and 5μm non-decalcified 
cryo-sections were obtained using a cryostat (HM505E; Microm, Walldorf, Germany). Sections 
were stained with 2% Alizarin red for calcium deposition and 2% silver nitrate for phosphate 
detection (von Kossa staining), and immunostained for GFP to detect the transplanted MDSCs. 
For GFP immunostaining, non-decalcified sections were rinsed in PBS, blocked in 10% horse 
serum and incubated overnight at 4°C with rabbit anti-GFP antibody (ab290; Abcam, 
Cambridge, MA) in 5% horse serum. After washing, sections were incubated for 1h at room 
temperature with biotin-labeled horse anti-rabbit IgG antibody. Biotin-immune complexes were 
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detected using the ABC and diaminobenzidine (DAB) peroxidase substrate kit (Vector, 
Burlingame, CA). All images were acquired using an upright bright-field microscope (Eclipse 
E800; Nikon, Tokyo, Japan). The number of GFP positive cells within and at the edge of the 
osteoid were also counted and normalized to bone surface (mm2) using NIH ImageJ Version 
1.46r software.   
5.2.9 Statistical analysis 
Statistical tests were performed using SPSS 16.0 (SPSS Inc, Chicago, IL). Data was tested for 
normality and equal variance before analysis. Statistical differences were calculated using 
analysis of variance (ANOVA or ANOVA on ranks if equal variance testing failed). Differences 
were considered significant at p<0.05. 
5.3 RESULTS 
To determine loading efficiency, the amount of BMP2 in the supernatant and coacervate pellet 
after centrifugation was determined by western blotting. 98.2% of the BMP2 was detected in the 
pellet, indicating that the coacervate loaded the BMP2 with high efficiency, and the remaining 
unloaded BMP2 was detected in the supernatant (Fig. 36a). The heparin:BMP2 molar ratio used 
for the ectopic bone formation experiments in vivo was approximately 20:1. Assuming a 1:1 
binding interaction between BMP2 and heparin, the coacervate has a theoretical loading potential 
of 20-times the amount of BMP2 used for in vivo experiments. The release profile of BMP2 from 
the coacervate into Dulbecco’s phosphate buffered saline (DPBS) was determined by pelleting 
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the BMP2 coacervate by centrifugation and measuring the concentration of free BMP2 in the 
supernatant at various time points using ELISA. Less than 1% of the BMP2 was detected in the 
supernatant immediately after forming the coacervate, confirming the high loading efficiency 
determined by western blot. A minimal burst release of only 1.3% after one day was observed 
(Fig. 36b). Thereafter, release was linear until day 10 when the release rate slowed and then 
sustained through the end of the experiment. After 28 days, approximately 25% of the BMP2 had 
been released from the coacervate. The data indicated that the coacervate can efficiently control 
the release of incorporated BMP2.  
 
 
 
Figure 36.  Loading efficacy and release profile of BMP2 from the coacervate.   (A) BMP2 coacervate 
was centrifuged and the amount of BMP2 in the pellet (P) and supernatant (S) were determined by western blot. An 
equal quantity free BMP2 served as the control (C) and loading efficiency was calculated as percent band intensity 
of the control. Western blot revealed that 98.2% of BMP2 was in the pellet, indicating a high loading efficiency. (B) 
BMP2 was released from the coacervate into DPBS at 37°C. Percent release over 28 days was quantified by ELISA. 
Data represent the mean ± SD (n=3). 
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5.3.1 Effect of the coacervate on MDSC proliferation 
The influence of the coacervate (PEAD:heparin) on the proliferation of MDSCs was tested by 
adding different concentrations of coacervate to the culture media and assessing cell proliferation 
after 3 and 5 days by DNA quantification (Fig. 37). No significant differences were seen among 
the groups at days 1 and 3; however, at day 5, the coacervate inhibited the growth of the MDSCs 
in a dose-dependent manner at concentrations above 0.125mg/ml. The coacervate at 0.125mg/ml 
showed no difference from the control and therefore had no inhibitory effects on MDSC growth. 
This concentration was consequently used for all the following experiments, including the in vivo 
tests.  
 
 
 
Figure 37.  MDSC proliferation with the coacervate.  MDSC proliferation was assessed by quantifying 
DNA content after 1, 3, and 5 days of culture with 0.125, 0.25, or 0.5 mg/ml coacervate in the culture media. The 
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control group contained only normal basal media without PEAD:heparin coacervate. Data represent the mean ± SD; 
*P<0.05 (n=4). 
 
5.3.2 Bioactivity of BMP2 released from the coacervate 
One important feature of a growth factor delivery vehicle is its ability to maintain growth factor 
bioactivity. We assessed this capability of the coacervate by stimulating ALP expression of the 
myogenic cell line, C2C12, with coacervate-released BMP2. Evaluating the expression of this 
pre-osteoblast marker in C2C12 cells is a common method of determining the activity of BMPs 
[362-364]. 100ng of BMP2 coacervate was compared to an equal amount of free BMP2 and 
control groups included DPBS and the delivery vehicle (coacervate) alone (Fig. 38). After 5 days 
of culture, BMP2 released from the coacervate induced significant expression of ALP by the 
C2C12 cells compared to the control. Furthermore, the ALP expression level induced by the 
BMP2 coacervate was significantly greater than induction with the same amount of free BMP2. 
As expected, the delivery vehicle alone had no effect on ALP expression by the C2C12 cells 
compared to the DPBS control and ALP staining showed similar results. The data suggests that 
the coacervate delivery system can preserve or even enhance the bioactivity of delivered BMP2 
compared to free BMP2. 
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Figure 38.  Bioactivity of delivered BMP2. C2C12 cells were cultured in media supplemented with DPBS 
as a control, delivery vehicle (coacervate only), free BMP2, or BMP2 coacervate. BMP2 dosage in the free BMP2 
and BMP2 coacervate groups was equal. (A) Representative images of ALP staining of cultured cells at day 5(10X). 
(B) ALP activity was evaluated at day 5 and normalized by DNA content. Data represent mean ± SD; *P<0.05 
(n=4). 
 
5.3.3 Effects of BMP2 coacervate on the osteogenesis of MDSCs in vitro 
Upon stimulation with BMP2, MDSCs undergo osteogenic differentiation which can be 
evaluated by their expression of ALP [343, 346]. The efficacy of sustained delivery of BMP2 for 
inducing osteogenesis of MDSC was tested in both monolayer and in a 3-D fibrin gel, 
representing a potential scaffold for cell delivery to a bone defect. After 5 days in monolayer 
culture, the ALP activity of the MDSCs was effectively stimulated with 100ng of BMP2 
coacervate while an equal single dose of free BMP2 showed no difference from the negative 
control and the coacervate only groups. (Fig. 39a). A multi-dose free BMP2 group was also 
included to mimic sustained release conditions with an equal dose of free BMP2 being added 
every two days. This amounted to a 3-fold higher total dosage of BMP2 (300ng) compared to the 
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BMP2 coacervate group (100ng). Multi-dose free BMP2 group did stimulate ALP activity, 
indicating that MDSCs require more than just a single initial exposure to free BMP2 to be 
effective; however, the ALP expression of this multi-dose BMP2 group showed no statistical 
difference from the BMP2 coacervate group, nor was there a difference between the BMP2 
coacervate group and the BMP4-transduced MDSCs group (positive control), which was also 
supported by positive ALP staining (Fig. 39c). RT-PCR analysis showed the mRNA expression 
level of Runx.2 were slightly higher in MDSCs that stimulated by free BMP2 and BMP2 
coacervate when compare to the control. However, no significant differences were found among 
groups. The mRNA expression level of Collagen type 1 significantly increased in MDSCs that 
were stimulated by BMP2 coacervate when compared to the MDSCs in control and single dose 
free BMP2 groups. No difference was observed between the multi-dose free BMP2 and BMP2 
coacervate groups (Fig. 39d). This further confirms the notion that the coacervate delivery 
system can potentiate BMP2 activity with a lower dose producing a similar effect to 3-fold 
amounts of free BMP2.  
To better mimic the in vivo environment, the effects that BMP2 coacervate had on the 
osteogenesis of the MDSCs were also examined in a 3-D fibrin gel culture system (Fig. 39b). 
Contrary to the results from the monolayer cultures, after 5 days of culture in fibrin gel, free 
BMP2 induced ALP expression above that of the control groups, possibly attributable to growth 
factor protection from degradation afforded by fibrin gel itself. Even so, BMP2 coacervate 
stimulated significantly more (approximately 2-fold) ALP activity compared to equal amount of 
free BMP2 (Fig. 5B). It should also be noted that the amount of BMP2 available to the cells in 
the BMP2 coacervate group was lower due to the nature of controlled release. The release assay 
indicated that less than 10% of the BMP2 was released by the coacervate after 5 days in vitro. 
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These data indicate that sustained release of BMP2 by the coacervate was more efficient than 
free BMP2 at stimulating osteogenesis of MDSCs in a 3-D fibrin gel environment.  
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Figure 39. Osteogenic potential of MDSCs in monolayer and 3-D culture in vitro.   (A) ALP 
expression of MDSCs after 5 days of monolayer culture, exposed to a single dose of 100ng free BMP2 or BMP2 
coacervate, or to 100ng BMP2 at three different time points to mimic controlled release (Multi-dose free BMP2). 
Control groups were exposed to DPBS only (Control) or the coacervate only without BMP2. (B) ALP expression by 
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the MDSCs after 5 days of culture in a 3-D fibrin gel, exposed to 100ng free BMP2 or BMP2 coacervate or DPBS 
only as a control. Data represent mean ± SD; *P<0.05 (n=4). (C) Representative images of ALP staining of 
monolayer cultured MDSCs at day 5 (10X). (D) RT-PCR analysis of the expression of Runx.2 and COL1A1 in 
MDSCs after 5 day culture. Expression of the specific markers were normalized to β-actin and then scaled according 
to the control sample. This value was set to 1. Data represent mean ± SD; *P<0.05 (n=3)   
 
5.3.4 Effects of BMP2 coacervate on the osteogenesis of mouse MDSCs in vivo 
We next examined the ability of BMP2 coacervate to stimulate the osteogenic potential of 
MDSCs in a mouse ectopic bone formation model. Free BMP2 or BMP2 coacervate, with or 
without MDSCs, was suspended in fibrin glue, to keep the cells and coacervate localized, and 
then implanted into a muscle pocket created in the hind limbs of mice. All mice survived the 
experiment and no complications such as infection or peripheral nerve damage were observed. 
Quantification of calcified tissue (bone volume) by 3D Micro-CT analysis revealed extensive 
bone formation by the MDSCs stimulated with BMP2 coacervate 2 weeks after implantation and 
the amount of bone increased at 4 weeks (Fig. 40a,b). MDSCs with free BMP2 showed minimal 
bone formation at week 2 and also increased in volume by week 4 (Fig. 40a,b). BMP2 
coacervate alone showed some bone formation at week 2 but no increase by week 4. MDSCs 
alone showed no significant bone formation at either time point, similar to the control group of 
fibrin gel alone (Fig. 40a,b). Significantly greater bone volume was formed by the MDSCs 
stimulated by BMP2 coacervate compared to all other groups at both time points; bone volume 
was 9-fold greater at week 2 and 4.5-fold greater at week 4 compared to the free BMP2+MDSC 
group (Fig. 38b).   
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Histological analysis included both Alizarin red staining and von Kossa staining to verify 
the calcium phosphate deposition and immunohistochemical (IHC) staining for GFP to 
determine the location of GFP-labeled MDSCs. Alizarin red and von Kossa staining revealed 
calcified osteoid matrix at the implantation site in the BMP2 coacervate only, free 
BMP2+MDSCs, and BMP2 coacervate+MDSCs groups, which is consistent with the Micro-CT 
data (Fig. 40c). This newly formed osteoid was abutting and expanding within the normal 
muscle tissue and the interface between the muscle and newly formed bone was clearly 
detectable. The myofibers adjacent to the ectopic bone formation appeared morphologically 
normal with a slight compression in the transition zone (Fig. 40c). Calcified osteoid matrix was 
found mostly at the edge of the transplantation area in the BMP2 coacervate only group but was 
found throughout the transplantation area in the free BMP2-MDSCs group and in the BMP2 
coacervate+MDSCs group which also displayed a more mature trabecular bone structure (Fig. 
40c). To determine whether the newly formed bone was derived from the transplanted MDSCs 
or from local host cells, MDSCs were labeled with GFP and then stained 
immunohistochemically. In the BMP2 coacervate only group, no GFP was detected in the newly 
formed bone osteoid which must therefore be derived from the host cells (Fig. 40c). In the free 
BMP2+MDSCs and BMP2 coacervate+MDSCs groups, cells expressing GFP were identified 
throughout and at the edge the osteoid with significantly more GFP positive cells observed in the 
BMP2 coacervate+MDSCs group (Fig. 40c). The transplanted MDSCs were closely associated 
with the newly formed osteoid, consistent with the hypothesis that the MDSCs were not only 
present within the osteoid but also active in the bone formation. Quantification of GFP-positive 
cells within, and the at the edge of the osteoid showed significantly higher numbers in the BMP2 
coacervate+MDSCs group than in the free BMP2+MDSCs group (Fig. 40d). 
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Figure 40.  In vivo effects of BMP2 coacervate on the osteogenesis of MDSCs.   (A) Representative 
Micro-CT images of ectopic bone formation after 2 and 4 weeks. Groups were transplanted with a fibrin gel 
containing 2µg free BMP2 or BMP2 coacervate alongside MDSCs, the BMP2 coacervate alone, MDSCs alone, or 
fibrin gel alone (Control).  (B) Ectopic bone volume (BV) quantification of Micro-CT images after 2 and 4 weeks. 
Data represent the mean ± SD; *P<0.05 (n=6). (C) Representative images of newly formed bone with Alizarin red 
staining (red, scale bars=200µm), von Kossa staining (black, scale bars=200µm) of calcified osteoid matrix, and 
immunohistochemical (IHC) staining for transplanted MDSCs (GFP-positive, brown, scale bars=50µm). (D) 
Quantification of the number of GFP-positive cell within and at the edge of the osteoid per mm2 of bone surface; 
*P<0.01 (n=6).  
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5.3.5 Effects of BMP2 coacervate on human MDSCs in vitro and in vivo 
hMDSCs were stimulated in vitro with a single free BMP2 dose (100ng) or BMP2 coacervate 
containing 100ng of BMP2 for 3 days. The ALP expression was significantly higher in the 
BMP2 coacervate group compared to the free BMP2 group (Fig. 41a). We observed significantly 
more ectopic bone after 2 and 4 weeks in the BMP2 coacervate+hMDSC group when compared 
to the other groups (Fig. 41b). Furthermore, when we transplanted hMDSCs with free BMP2 or 
with BMP2 coacervate into 5mm critical-size calvarial defects created in CD1 mice, microCT 
evaluation after 2 weeks revealed significantly larger bone volume in the BMP2 coacervate 
group compared to the free BMP2 group (Fig. 41c,d). The same population of hMDSCs 
(1.5x106 cells) transduced with lenti-BMP2 was used as a positive control group (BMP2-
transduced hMDSCs). Interestingly, there was no significant difference between the BMP2 
coacervate+hMDSC and BMP2 transduced hMDSC groups. By 4 weeks we observed only 
partial healing of the defect in the free BMP2+hMDSC group. In contrast, the bone defect in the 
BMP2 coacervate group was almost completely covered with regenerated bone, which was 
similar to the BMP2-transduced hMDSC group (no significant difference was observed between 
these two groups). These results taken together suggest that the BMP2 coacervate could 
represent a BMP2 delivery system of choice when combine with hMDSCs to enhance bone 
repair in order to accelerate the clinical translation of our work, without the requirement of gene 
therapy. 
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Figure 41.  Osteogenic potential of human MDSCs.  A) In vitro ALP expression assay. *P<0.05. B) 
Quantification of in vivo ectopic bone formation model. *P<0.05. C) Representative µCT images of in vivo cranial 
defect model. D) Quantification of in vivo cranial defect bone formation model. *P<0.05. 
 
5.4 DISCUSSION 
Skeletal muscle is a good source of various cellular progenitors with potential musculoskeletal 
therapeutic applications [338, 339, 343]. Muscle-derived stem cells (MDSCs) are a population of 
cells that can be isolated by a modified pre-plate technique from mouse skeletal muscle and 
display a superior regeneration capacity in various musculoskeletal tissues, including skeletal 
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and cardiac muscles, bone, and articular cartilage when compared to myoblasts [344, 350-352]. 
MDSCs demonstrate the capacity for self-renewal, long term proliferation, multi-potent 
differentiation, and have a superior ability for survival due to their increased resistance to 
oxidative and inflammatory stresses [365]. MDSCs are therefore an alternative cell source, other 
than bone marrow or fat tissue derived mesenchymal stem cells, for bone tissue engineering.  
Since local stimulation of MDSCs by BMPs following transplantation is essential for 
osteogenic differentiation, maintaining an adequate concentration of stable, active BMPs at the 
transplantation site is necessary. Unfortunately, for most clinical applications requiring cell 
transplantation such as bone non-union, delayed non-union, and large bone defects, local BMP 
shortage is a primary cause for insufficient healing. Without supplementation of exogenous 
BMPs, most transplanted progenitor cells, such as mesenchymal stem cells (MSCs), fail to 
undergo osteogenic differentiation and eventually form fibrous tissue instead of functional bone 
[366, 367]. More importantly for the current study, non-transduced MDSCs do not undergo 
osteogenic and chondrogenic differentiation when transplanted into bone and articular cartilage 
defects in vivo, rather they undergo default myogenic differentiation [355, 356]. Simply 
incorporating recombinant BMP protein within a commonly used soluble scaffold such as fibrin 
glue, fails to sufficiently stimulate MDSCs to undergo osteogenesis [356]. Additionally, the half-
lives of BMPs in the body are very short, on the order of minutes to hours [357, 358]. As a result, 
large doses of BMP are often required to obtain the desired osteogenic effect [368]. Many studies 
use doses on the order of 1000 times greater than can be found in the entire human body, 
drawing concerns with regards to cost and safety [369, 370]. With such short half-lives and rapid 
dilution in the body, even these large doses may not provide adequate local concentrations at 
critical times to optimally induce bone formation by the transplanted cells. As a result, controlled 
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delivery systems that supply active BMPs alongside the transplanted progenitor cells to promote 
osteogenesis are highly important for the future of cell-based bone regeneration strategies. 
Developing suitable carriers for BMPs that can preserve their bioactivity and sustain their 
release over time presents a great challenge. To date, a number of systems have been designed 
and evaluated for the delivery of BMPs, including gelatin/β-tricalcium phosphate [371], collagen 
gel [372], poly-L-lactic acid scaffolds [373], a porous hydroxyapatite composite [374], 
hyaluronic acid [375], and fibrin gel [375]. Bovine type I collagen is currently used in the 
clinical setting as a carrier and has been approved by the Food and Drug Administration for spine 
fusion in humans [376, 377]. These delivery systems have been shown to enhance bone repair 
and accelerate fracture healing to some degree; however, they often suffer issues inherent to poor 
control over release rate such as low loading efficiency and a large initial burst release of the 
protein [371-373]. Furthermore, the use of harsh organic solvents in the synthesis of many 
polymeric delivery systems may denature loaded growth factor proteins and reduce their 
bioactivity [378]. Clearly, a controlled release system that avoids these common setbacks could 
greatly advance the field of growth factor delivery for bone regeneration.  
In the current study, a PEAD:heparin growth factor delivery system was designed and 
utilized to provide continual release of BMP2 alongside the transplanted MDSCs. Heparan 
sulfate glycosaminoglycans are a natural component of the extracellular matrix with a high 
affinity for many growth factors and cytokines. Heparin has a similar structure and is commonly 
incorporated into delivery systems for heparin-binding growth factors. Heparin binds BMP2 with 
high affinity [379] and has been previously shown to retain its bioactivity well [357, 380, 381]. 
In the presence of heparin, degradation of BMP2 is reduced and its half-life in culture media is 
prolonged 20-fold [357]. To best preserve heparin in its intact form and maintain its full 
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functionality we used a polycation which complexes with heparin by charge interactions. PEAD 
is a synthetic polycation with a high charge density, easy synthesis, and good biocompatibility 
[212]. Heparin and bound growth factors precipitate out of the aqueous solution upon interaction 
with PEAD to form a self-assembled coacervate. Once incorporated in the coacervate, growth 
factors are protected from degradation and slowly released over time based on disassembly of the 
complex in an ionic environment and hydrolytic degradation of PEAD [212]. Our data using 
both C2C12 cells and MDSCs demonstrated the retained bioactivity of BMP2 released from the 
coacervate. Furthermore, BMP2 coacervate stimulated higher cellular ALP activity than equal 
dose of free BMP2, and showed similar results to a 3-fold higher total dose of free BMP2 added 
at multiple times during the experiment. These results indicate that the coacervate may directly 
potentiate the activity of BMP2 beyond what is inherent to sustained release. Indeed, heparin has 
been shown to modulate the interactions between heparin-binding growth factors and their 
receptors [382, 383], and likely plays a similar role in promoting the bioactivity of BMP2 [381]. 
Moreover, heparin has also been shown to protect BMP2 from the inhibition by noggin, which is 
induced to express as part of the negative feedback loop in response to BMP2 expression [357].   
Pharmacokinetic models of BMP release from collagen sponges and other common 
delivery vehicles show rapid initial effluxes, during which the carrier can lose 30% or more of its 
loaded BMP [384, 385]. This initial burst release spikes the BMP concentration in the 
surrounding tissue to supraphysiological levels which can result in severe complications such as 
ectopic bone formation in the spinal canal, haematomas in soft tissue, and bone resorption 
around implants [386-389]. Clearly such systems are inefficient and potentially harmful. 
Conversely, the PEAD-heparin delivery system loaded BMP2 with high efficiency (98.2% 
loading), showed a negligible initial burst release (1.3% after one day), and thereafter produced 
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slow and sustained release for at least 4 weeks. Our in vivo results showed extensive bone 
formation by the transplanted MDSCs and minimal participation of surrounding host tissue cells, 
which indicates the local preservation of BMP2 activity and the efficacy of sustained release of 
BMP2 on the osteogenesis of the donor MDSCs. The released BMP2 did not appear to have any 
significant effect on the surrounding tissue, indicating that the coacervate localizes the BMP2 to 
the site of implantation. Our in vitro data showed only 25% of the BMP2 was released after 28 
days, yet release is expected to be accelerated in vivo where degradation of the polyester 
backbone of PEAD is catalyzed in the presence of hydrolases [390]. Hydrolases may also be 
secreted by the MDSCs which could contribute to the targeting of BMP2 release on the 
transplanted cells.  
In the present study, the coacervate served as a multi-functional vehicle for growth factor 
delivery. The coacervate naturally loads any heparin-binding growth factor, enabling co-delivery 
of other factors alongside BMP2 in the future. Of particular importance may be angiogenic 
growth factors to incite the formation of a supportive vascular network to enhance MDSC 
survival and osteogenesis. Additionally, the strongly polyvalent nature and many free functional 
groups of the PEAD-heparin coacervate enable easy coating onto a wide range of materials. Held 
by relatively weak Coulombic forces and hydrogen bonding, the release functionality of the 
delivery system is unlikely to be affected. This could be useful for stimulating host cell seeding 
of osteo-inductive scaffolds in situ, or to improve the osteogenesis of cells seeded into scaffolds 
ex vivo. 
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5.5 CONCLUSIONS 
This study demonstrated that a dual cell and growth factor delivery approach may serve as a 
viable therapy for muscle cell based bone regeneration. The controlled delivery of BMP2 from 
[PEAD:heparin] coacervate can sufficiently stimulate hMDSCs to differentiate into an 
osteogenic lineage, both in vitro and in vivo. Lastly, hMDSC combined with BMP2 coacervate 
showed comparable reparative potential to genetically modified hMDSCs. Therefore, the 
implantation of non-genetically modified hMDSCs to the injury site with an effective BMP 
delivery system is a practical option for patients in terms of both safety and long term results. 
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6.0  FINAL CONCLUSIONS AND FUTURE DIRECTIONS 
Here I describe the development of three regenerative therapies for three distinct biomedical 
applications: skin wound healing, cardiac repair, and bone regeneration. Each approach consists 
of the three key components of all regenerative therapies: cells, scaffolds, and signals. Based on 
the application, for each component I chose to apply it exogenously or to rely on provision by the 
body. For wound healing I applied HB-EGF and relied on endogenous scaffolding and cells to do 
the rest (Fig. 42a). For cardiac repair I included a PEG scaffold along with Shh but relied on the 
body’s own cells to complete the regenerative therapy (Fig. 42b). Finally, for bone regeneration 
I applied BMP2, a fibrin gel, and MDSCs because the body could not sufficiently supply any of 
these components (Fig. 42c). And in all three cases we appreciate the importance of the 
extracellular matrix in the form of a biomimetic coacervate which I demonstrated was imperative 
to the success of each therapy (Fig. 42d). 
  
 149 
 
Figure 42.  Regenerative therapies for three biomedical applications.  A) Wound healing required HB-
EGF and the body provided the scaffold and cells. B) Cardiac repair required Shh and PEG hydrogel and the body 
provided the cells. C) Bone regeneration required BMP2, a fibrin gel, and MDSCs. D) The three therapies are linked 
by use of a biomimetic coacervate which imitates the role of the ECM in facilitating growth factor signaling in the 
body. 
 
  
 The ultimate goal of the experimental therapies described here are better clinical 
treatments for diabetic ulcers, heart failure, and bone defects. Each therapy will require 
validation in large animal studies and controlled clinical trials; growth factor dosage and 
application method will require optimization at each step. However, this dissertation lays the 
foundation, and furthermore should fuel the development of new and innovative regenerative 
therapies for other diseases in the 21st century.   
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